Revision as of 08:01, 16 January 2013 editDidymus Judas Thomas (talk | contribs)161 editsm →Suggested addition of "Burzynski Clinic" Section, edit/removal of non-referenced/sourced material← Previous edit | Latest revision as of 10:49, 31 December 2024 edit undoHob Gadling (talk | contribs)Extended confirmed users18,522 edits remove botched section | ||
Line 1: | Line 1: | ||
{{Talk header |
{{Talk header|search=yes}} | ||
{{Controversial}} | |||
{{Not a forum}} | |||
{{WikiProject banner shell|blp=yes|class=B|1= | |||
{{WikiProject Skepticism|importance=Mid|needs-infobox=no}} | |||
{{WikiProject Medicine|importance=Low|infobox-requested=no|needs-photo=Yes}} | |||
{{WikiProject Alternative medicine}} | |||
{{WikiProject United States|importance=Low|TX=yes|TX-importance=Low|needs-infobox=no|image-needed=Yes|map-needed=no|geocoord-needed=No|image-in=Texas|map-in=Texas}} | |||
}} | |||
{{Press | |||
| subject = article | |||
| author = Jack Hitt | |||
| title = Inside the Secret Sting Operations to Expose Celebrity Psychics | |||
| org = ] | |||
| url = https://www.nytimes.com/2019/02/26/magazine/psychics-skeptics-facebook.html | |||
| date = February 26, 2019 | |||
| quote = Collectively, the group, which has swelled to 144 members, has researched, written or revised almost 900 Misplaced Pages pages. ... they have provided facts about the Burzynski Clinic, a theoretical treatment for cancer operating out of Houston. | |||
| accessdate = January 29, 2020 | |||
}} | |||
{{Copied |from=Burzynski Clinic |from_oldid=509758461 |to=Stanislaw Burzynski |to_diff=509759041 |to_oldid=509730018 |date=12:03, 29 August 2012}} | |||
{{ArbComPseudoscience}} | |||
{{User:MiszaBot/config | {{User:MiszaBot/config | ||
|archiveheader = {{aan}} | |archiveheader = {{aan}} | ||
|maxarchivesize = 100K | |maxarchivesize = 100K | ||
|counter = |
|counter = 8 | ||
|minthreadsleft = |
|minthreadsleft = 8 | ||
|algo = old(90d) | |algo = old(90d) | ||
|archive = Talk:Burzynski Clinic/Archive %(counter)d | |archive = Talk:Burzynski Clinic/Archive %(counter)d | ||
}} | }} | ||
{{Auto archiving notice |bot=MiszaBot I |age=3 |units=months }} | |||
{{User:HBC Archive Indexerbot/OptIn | {{User:HBC Archive Indexerbot/OptIn | ||
|target=/Archive index |mask=/Archive <#> |leading_zeros=0 |indexhere=yes | |target=/Archive index |mask=/Archive <#> |leading_zeros=0 |indexhere=yes | ||
}} | }} | ||
{{WikiProjectBannerShell|blp=yes|1= | |||
{{WikiProject Rational Skepticism|class=C}} | |||
{{WikiProject Medicine|class=C|importance=Low}} | |||
{{WikiProject Alternative medicine|class=C}} | |||
}} | |||
{{off topic warning}} | |||
{{Caution|'''Important notice''': Some common points of argument are addressed in the FAQ below, which represents the ] of editors here. Please remember that this page is only for discussing Misplaced Pages's ''encyclopedia article'' about the Burzynski clinic.}} | |||
{{FAQ|collapsed=no}} | |||
{{controversial}} | |||
{{Copied |from=Burzynski Clinic |from_oldid=509758461 |to=Stanislaw Burzynski |to_diff=509759041 |to_oldid=509730018 |date=12:03, 29 August 2012}} | |||
== Warning to editors watching this page. == | |||
Apparently there is a group of Burzynski supporters that are crowd-sourcing others to come edit this page. Some reference that we have been using quotes out of context and other claims. Here is one "the issue is, they block any new or old users from editing it, and Wiki has no way to police it. It's a brick wall. The article also breaks all sort of Wiki rules, such as posting quotes out of context, etc. especially in the "review' section of this film. They even used a quote from the Houston Press "reviewing" my film, when the linked article/source for this review clearly states that I refused an advance copy of the film to the writer—meaning the "reviewer" never actually viewed the film at all. The list is endless." If we are in error then we to clean up these problems. | |||
Here is another post from someone ready to bring it on. "Merrill Aldighieri I don't have accurate stuff to fill in. If you want to send me some preferred text, I will paste it in whenever i have a free minute to spare. I am not a pro at coding though, i can only cut and paste raw text. Don't know how to make bold headers or add footnotes, etc." | |||
Just want to bring this to the attention of everyone. https://www.facebook.com/permalink.php?story_fbid=10151240453868442&id=318281183441 ] (]) 03:00, 10 November 2012 (UTC) | |||
:I don't see where we state Malisow reviewed the film. ] (]) 21:42, 10 November 2012 (UTC) | |||
:I guess watch out for meat puppets as well. ] (]) 21:45, 10 November 2012 (UTC) | |||
::The Malisow stuff (last words of the article) does have a couple of problems. First, the article makes it seem as if he is criticizing the film ''itself'', rather than (more precisely) the nature of the film-making project which would inevitably end in a biased film (which he had not seen). Secondly, he is called "Cory Malisov" when his name is in fact "Craig" ... I have tried to correct/tidy this with an edit. ] (]) 09:36, 11 November 2012 (UTC) | |||
== Quote grossly taken out of context. Breaks all ethical rules of Misplaced Pages. == | |||
{{edit semi-protected|answered=yes}} | |||
<!-- Begin request --> | |||
"Prior to the debut of "Burzynski", Houston Press correspondent Craig Malisow mocked the film’s lack of objectivity, characterizing it as "a puff-piece paean that cherrypicks facts and ignores any criticism", and criticized the project for presenting only Burzynski's side of the story." | |||
This breaks all ethical rules of Misplaced Pages. Craig Malisow never watched the film—ever. he states so in his own article: ""If anyone out there has seen the movie, please let us know your thoughts." | |||
The grossly taken out of context quote says: "... '''we don't necessarily think''' its a puff-piece paean that cherrypicks facts and ignores any criticism of a documentary's subject is a truly horrible thing, as long as viewers understand they're just getting one side of the story." | |||
source: http://blogs.houstonpress.com/hairballs/2010/06/burzynski_movie.php | |||
<!-- End request --> | |||
] (]) 23:27, 9 December 2012 (UTC) | |||
:<del>This only confirms that at least some of the authors of his article were engaged in an anti-Burzynski crusade, even at the cost of NPOV. Sad to see this on Misplaced Pages. Feel free to remove the entire sentence from the article as it brings nothing new except for more rant.</del> <span style="font-family: 'Candara', sans-serif; font-weight: bold; text-shadow: #AAAAFF 0.2em 0.2em 0.1em; class: texhtml">]</span> 01:41, 10 December 2012 (UTC) | |||
:Uh, the quote is, "We're not sure which dictionary Merola has consulted for his understanding of the word "objective," but hey -- we don't necessarily think a puff-piece paean that cherrypicks facts and ignores any criticism of a documentary's subject is a truly horrible thing, as long as viewers understand they're just getting one side of the story." Way to misquote the quote. Your addition of the word "its" in that quote that actually isn't there completely changes the meaning of the sentence. Oh, the irony. ] (]) 01:52, 10 December 2012 (UTC) | |||
{{notdone}} A pretty poor misrepresentation of a source, and accusation of bad faith above (kashmiri – did you check the source before responding thus?) — come on people: please raise the standard! ] (]) 05:51, 10 December 2012 (UTC) | |||
:No I haven't, I assumed ], thanks for pointing out. On the other hand, it's hard to avoid an impression that the selection of reviews has been done here somewhat one-sidedly. <span style="font-family: 'Candara', sans-serif; font-weight: bold; text-shadow: #AAAAFF 0.2em 0.2em 0.1em; class: texhtml">]</span> 10:09, 10 December 2012 (UTC) | |||
::Kashmiri — I think, to be fair, you assumed good faith from one quarter, but not from another. ] (]) 10:32, 10 December 2012 (UTC) | |||
:::That looks a bit ]. Nevertheless, it has been repeatedly pointed out here that the article contains many unverified or biased edits; yet, editing attempts were promptly being reverted. It seems ok to include a detailed list of legal charges against Burzynski Institute but when someone added that BI had been cleared of the charges this was immediately removed as "biased". Sure, in "good faith"? <span style="font-family: 'Candara', sans-serif; font-weight: bold; text-shadow: #AAAAFF 0.2em 0.2em 0.1em; class: texhtml">]</span> 11:37, 10 December 2012 (UTC) | |||
::::Yes, I hope you ''personally'' recognize that assuming good faith means assuming it from all quarters, otherwise there's not much point, is there? As to your points of substance, what in the article is unverified? If there is such content either remove it, tag it, discuss it here or (best of all) find a source! On legal cases, is there a case described here where the charges are mentioned but the result not? We should include results of legal actions (when known) if the action is mentioned. ] (]) 11:53, 10 December 2012 (UTC) | |||
:::::Thank you for you lecturing me again, Alex. As to unverified claims, just go and read this Talk page carefully from the beginning, I don't feel like copying and pasting things that have been written above. As to the administrative complaint against Burzynski Institute, see this recent edit: http://en.wikipedia.org/search/?title=Burzynski_Clinic&diff=527085071&oldid=527062868. <span style="font-family: 'Candara', sans-serif; font-weight: bold; text-shadow: #AAAAFF 0.2em 0.2em 0.1em; class: texhtml">]</span> 15:41, 10 December 2012 (UTC) | |||
__TOC__ | |||
::::::No problem, Kashmiri. On unverified material, I see some complaints above that fail to appreciate that introductory/summarizing content doesn't ''need'' to be sourced if the content is sourced in more detail later. Why not stick "fact" templates on things you consider to be unsourced? Quite apart from anything else, it's a good deal quicker than typing stuff on the talk page. For the edit, I'm not quite getting your point ... I see the edit; I see the revert ... is there any follow-up discussion? or is that what you are initiating now? If so, I suggest starting a new section here. ] (]) 16:21, 10 December 2012 (UTC) | |||
== Good Evidence for Antineoplaston Efficacy from Japan == | |||
== Suggested addition of "Burzynski Clinic" Section, edit/removal of non-referenced/sourced material == | |||
A 2015 study from Ogata et al. titled "<u>Randomized Phase II Study of 5-Fluorouracil Hepatic Arterial Infusion with or without Antineoplastons as an Adjuvant Therapy after Hepatectomy for Liver Metastases from Colorectal Cancer</u>" (https://doi.org/10.1371/journal.pone.0120064) records that in an open label, non-blinded but randomized phase II study '''cancer specific survival rate (CSS) was significantly higher in the antineoplaston arm vs. the control (i.e. non-antineoplaston) arm.''' This study had 65 patients enrolled, with 33 of those in the control group not receiving antineoplaston therapy, and 32 receiving the treatment. Median survival in the antineoplaston group, was, in fact, 67 months vs. 39 months, with a CSS of 60% and 32%, respectively. Furthermore, there were no incidental serious toxicities or apparent liver or kidney damage. Now, I demand an answer on moral grounds: '''Why is this study not mentioned in this article?''' I hold a biochemistry degree and a master's degree in medical science and would like to know why this isn't mentioned in the article. | |||
I do not see a Section titled: "Burzynski Clinic." Please add one so suggested changes may be posted. | |||
Main Article has: "While the clinic does offer conventional chemotherapy and (via an associate center) radiotherapy," yet cites no source for these claims. I suggest they be removed if no referenceable source. Thank you very much.] (]) 09:39, 10 December 2012 (UTC)Didymus Judas Thomas 12/10/12 | |||
Additionally, Ushijima et al. in the journal <u>Oncology Reports</u> published an article called "<u>Demethylation effect of the antineoplaston AS2-1 on genes in colon cancer cells</u>" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868501/) which <b>clearly reports epigenetic changes in colon cancer cells,</b> changes which are very likely to suppress cancer development and progression using the body's natural tumor suppression system. This work from these researchers is highly suggestive, just as Dr. Burzynski has stated in on-the-record interviews, that epigenetic modulations in response to the presence of antineoplastons are, in whole or in part, how they fight cancer. | |||
:The article ''itself'' is entitled "Burzynski Clinic", so no section is required. I shall check sources for the claims of conventional therapy. ] (]) 10:01, 10 December 2012 (UTC) | |||
:I can't find anything, although the wording here is too specific to seem like it is invented; for the meantime this content can be removed — it is hardly essential to the article in any case. ] (]) 10:30, 10 December 2012 (UTC) | |||
While this is not absolute proof of antineoplaston therapy's efficacy, it is extremely favorable evidence and analysis, and I would just like to know how anybody could look at these studies and act as if the whole antineoplaston therapy question should just be dismissed as quackery. | |||
::My issue is that if you go on the Mobile site the 1st Section is "Burzynski Clinic," & the 2nd is "Stanislaw Burzynski," but if you go on the Desktop version & look at the Left side Table of Contents, there is no link to add Talk issues about the 1st Section of the "Burzynski Clinic" Article. On here the 1st Section is about the film. I should also state that when I've tried to use the Edit function I've received a message to | |||
the effect that it was vandalism so they removed it, which I then had to repost in Talk. Thank you very much.] (]) 12:03, 10 December 2012 (UTC)Didymus John Thomas 12/10/-2 | |||
Misplaced Pages - in fact, anybody - I ask you: why is none of this mentioned in the article on the topic? In fact, why are the staff at Misplaced Pages not seriously disturbed at the lack of research into this topic? How could anybody look at these studies and not demand further investigation? ] (]) 03:09, 22 January 2023 (UTC) | |||
::Article don't put opening paragraphs in their own section (a stylistic error, but who am I to argue?). See ]. ] (]) 18:26, 10 December 2012 (UTC) | |||
:Read ] and ]. We wait until there are favorable secondary sources that collect primary ones. That is also how competent scientists judge those things. Accepting primary studies at face value is naive and amateurish. --] (]) 06:49, 22 January 2023 (UTC) | |||
::I appreciate your reply. | |||
::1. Who said anybody should "just accept" this or that study "at face value"? - nobody, that's who. The point I made is that this is an example of a professional, independent, peer-reviewed clinical trial which produced results that unambiguously suggest that antineoplastons have clinical efficacy. Yes - duh, obviously - it could be a fluke - it's just that, ''without evidence to the contrary'' it is '''unlikely''' to be a fluke. Does such evidence exist, or not? No clinician in their right mind would say that "this single study means we need to start giving patients antineoplastons right away!" ...but no '''objective''' clinician could possibly look at that study and honestly say that this doesn't warrant interest. Given the history of the field any physician or researcher would be PERFECTLY within their rights to look at that study and say "meh, I'll bet it's a fluke - happens all the time," but '''that''' sort of reply is not science. Only follow-up studies that demonstrate no replication of effect WOULD be evidence. A study like that warrants follow up, and that's a plain fact. To ignore it wholesale in an article which is designed precisely to deal with the very controversy of the efficacy of the drugs is NOT objective or neutral. | |||
::2. Misplaced Pages's own policy (the one you linked me to) on Primary Sources (from "Reliable sources") states: | |||
::======= | |||
::"A primary source may be used on Misplaced Pages only to make straightforward, descriptive '''statements of facts''' that can be '''verified by any educated person with access''' to the primary source but without further, specialized knowledge. For example, an article about a musician may cite discographies and track listings published by the record label, and an article about a novel may cite passages to describe the plot, but any interpretation needs a secondary source." | |||
::======= | |||
::And here : | |||
::======= | |||
::'''''Primary''''' sources should NOT <b>normally</b> be used as a basis for biomedical content. This is because primary biomedical literature is exploratory and often not reliable (any given primary source may be contradicted by another). Any text that relies on primary sources should usually have minimal ], <b>only describe conclusions made by the source, and describe these findings so clearly that any editor can check the sourcing without the need for specialist knowledge. Primary sources should never be cited in support of a conclusion that is not clearly made by the authors</b> | |||
::======= | |||
::Mentioning the results of the aforementioned 2015 Ogata et al. study clearly would not violate the explicit, stated policy, and in fact would do wonders for the objectivity of the article. | |||
::3. This article currently says '''verbatim''' that "there is no clinical evidence of the efficacy of these methods." The authors throughout the Wiki article were very careful to be objective and only report the opinions of institutes and bodies that stated that antineoplastons were not effective, instead of making categorical statements of fact or categorically characterizing the entire extent field of evidence as one way or the other. That is objectivity. However, in the aforementioned statement, this standard was dropped and the article makes a categorical statement which is, in fact, false, because the 2015 Ogata et al. study is an exact contradiction to the statement. | |||
::4. I have no serious academic interest, economic incentive or personal conflict on this matter at all. I just care about objectivity and have an interest in healthcare. Surely you're a clinician or scientist of some kind (I would hope) - what exactly IS your view on the 2015 Ogata et al. study? Do you think it was a fluke? | |||
::I apologize for the length of my reply. ] (]) 16:05, 22 January 2023 (UTC) | |||
:::I have an idea of Hobs opinion, but instead I'm going to give you mine. For us encyclopedia editors, Ogata et al is entirely unimportant, because of ] and ]. - ]the ] 16:21, 22 January 2023 (UTC) | |||
::::Uncannily accurate. --] (]) 17:11, 22 January 2023 (UTC) | |||
::::Agree. ''']''' <small>(] - ])</small> 22:13, 24 January 2023 (UTC) | |||
:::Let me explain. When summarising the 2015 Japanese study, you quoted raw survival data. This means that you've disregarded the existence of confounders and, essentially, the entire statistical model. However, the study conclusion reads: "Overall survival was not statistically improved (''p''=0.105) in the AN arm (''n''=32). RFS was not significant (p=0.343)." As you may know, the ] indicates, in lay terms, to what extent the observed outcome can be credited to the studied intervention. Commonly, statistical models require ''p'' not to exceed 0.05 for the results to be considered ]. | |||
:::Here in this study, ''p'' was significantly higher, which essentially means that the observed outcome (e.g., difference in survival) has not been solely due to the intervention (antineoplaston therapy), since other factors have influenced it more strongly. | |||
:::To but it bluntly, the study offers some evidence that antineoplastons are not effective in the studied dose for this type of cancer (although, being an open-label study, its evidence value is anyway low). | |||
:::If you insist on including the paper, I'm ok with summarising it along the lines: ''In a 2015 randomised open-label study carried out in Japan, ] was ineffective as an adjuvant therapy for ] resulting from ].'' — ] ] 17:09, 22 January 2023 (UTC) | |||
::::Your analysis is excellent, and we should definitely not include it for those reasons. ''']''' <small>(] - ])</small> 22:15, 24 January 2023 (UTC) | |||
:::::], did you read the article before proclaiming Kashmirir's analysis excellent? ] (]) 04:31, 17 January 2024 (UTC) | |||
::::::Yes. My personal view: Primary sources with "antineoplastons" as an ''adjuvant'' therapy for ''liver'' cancer were, and remain, irrelevant to the inflated and entirely unsupportable claims by Burzynski for use of his quackery as a magical ''primary'' therapy (in the words of his stans, a cure) for incurable brain cancers, based on nearly half a century of utterly underwhelming results and large numbers of (well documented) dead patients bilked out of vast sums of money. | |||
::::::My Misplaced Pages policy view: Misplaced Pages is not here to blaze the trail in promoting commercial claims where the consensus in the relavant professional community is that tsaid claims are at best nonsense, and at worst entirely fraudulent. | |||
::::::When all the reliable secondary sources show he's a mendacious quack, so do we. ''']''' <small>(] - ])</small> 19:24, 17 January 2024 (UTC) | |||
:::::::It was a simple yes/no question - the 2015 Japanese study - did you read it before proclaiming Kashmirir's analysis excellent or not. Yes, you say. I believe you know what a ] is, and you know that the study that you read met its primary endpoint. And yet you insist an analysis is excellent that '''misrepresented''' that primary endpoint (p=0.037 for CSS) as not ]. That is '''not''' excellent analysis. It seems to me your preconceptions are clouding your judgement. That's the most charitable interpretation of the facts in front of me I can come up with. How do you explain it? I expected the science and data to show Burzynski's work to be without much merit. But what I'm finding so far is multiple extremely flawed criticisms based on falsehoods. One of which has already been acknowledged and fixed. ] (]) 02:10, 18 January 2024 (UTC) | |||
::::1. I'm sorry but did you not ''read'' the rest of the findings section you quoted from??! It's not even five or six sentences long! And the ''very next sentence'' <u>directly</u> after the one you quoted states: | |||
::::'''Nevertheless, the CSS rate was significantly higher in the AN arm versus the control arm (n=33) with a median survival time 67 months (95%CI 43-not calculated) versus 39 months (95%CI 28-47) (p=0.037) and 5 year CSS rate 60% versus 32% respectively.''' | |||
::::At the risk of being redundant, I will point out that the P-value is below the threshold of 0.05 <u>you</u> selected! Not that p = 0.05 is some "special" threshold - it's just a convention. Many researchers value a p of 0.1, some 0.05, some 0.01 - those are all not uncommon p values. Either way it doesn't matter since you chose the p of 0.05, which you must not have realized the study conclusion <u>did</u> in fact satisfy. Did you not read the paltry few sentences of the article summary? Or are you seriously purposefully distorting the information? (See #3 below) | |||
::::2. The Misplaced Pages policy states: "Any text that relies on primary sources should...'''only describe conclusions made by the source ... Primary sources <u>should never be cited in support of a conclusion that is not clearly made by the authors</u>''' | |||
::::Now, your suggested "summary" is a '''complete''' reversal of the conclusion the study authors reach, which is described in the single sentence - not difficult to read or see - in the "Interpretations" paragraph of the study: '''Antineoplastons (A10 Injection and AS2-1) might be useful as adjunctive therapy in addition to HAI after hepatectomy in colorectal metastases to the liver.''' To include YOUR summary of the article would be a <u>direct</u> violation of the Misplaced Pages guideline you originally invoked! | |||
::::3. Perhaps most telling of all, you either didn't read the paltry few sentences of the article summary, or had more insidious designs. I'm really just quite perplexed. | |||
::::(A) Your "explanation" - which this person "Guy" bizarrely praised as "excellent" - suggested that a summary of the article could be included as ''In a 2015 randomised open-label study carried out in Japan, ] was ineffective as an adjuvant therapy for ] resulting from ].'' | |||
::::Excuse me, but what...the hell? The study was not testing 5-fluorouracil! '''It''' was not the adjuvant! You obviously didn't understand the simple trial! The article was testing ''addition'' of antineoplastons TO a therapeutic HAI (Hepatic Arterial Infusion) of 5-fluorouracil - the 5-fluorouracil is not an antineoplaston and is a ''known chemotherapeutic'' for this adminstration route - which is WHY they were using it in the first place! The <u>antineoplastons</u> were being ''added as adjuvants'' to be tested - BOTH groups got 5-fluoruracil, ONE got the antineoplastons. | |||
::::(B) You obviously didn't understand the study despite it being incredibly simple. You didn't understand what was being tested, didn't know that 5-fluorouracil was not an antineoplaston, didn't know that 5-fluorouracil via HAI was a known chemotherapeutic, and thought that the data suggested 5-fluorouracil was ineffective, when in fact it is KNOWN to be effective, and the data in fact suggested that the antineoplaston WAS effective. I mean, this is just a ridiculous misinterpretation (or something) on your part - I'm sorry. | |||
::::4. While your characterization of a study on basic research as "utterly useless" regarding clinical applications is an absurd exaggeration, it's perfectly legitimate to suggest it doesn't belong in a subsection, perhaps, about clinical results of a trial of the drug. But to call such basic research "utterly useless" is mind-numbingly obtuse - you can't GET to clinical trials without some plausible mechanism or evidence buttressed by basic research. I have no problem not mentioning the known epigenetic activity of antineoplastons in a summary of ''clinical trials'' - but to say it just shouldn't be included '''anywhere in an article''' about Burzynski and his therapy on antineoplastons is asinine. It's a ''known'' effect of the drug in cancerous cell lines and you have huge portions of an article dedicated to - supposedly - objectively analyzing the efficacy, plausibility and suitability of Burzynski's therapy for cancer treatments! To dismiss it as "utterly useless" is absurd! | |||
::::5. I apologize for any overtly rude-sounding aggression but I was just left gobsmacked and dumbfounded by your response. I thought the people who would be editing a Misplaced Pages article about a supposed quack cancer treatment would be highly qualified experts in a closely related field, if not in the field itself. Instead it seems as if you weren't even familiar with a common chemotherapeutic agent, didn't know what kind of medication it was, and were unable to understand a simple article. | |||
::::6. Let me be clear: I have no intention to continuously revisit these posts over and over again, though perhaps I might if I must. I feel I have said enough that needs to be said and the record will show it here. As I said before I have NO serious dog in this fight or conflict of interest, and I even am SUSPICIOUS of Burzynski's therapy myself! 40+ years of antineoplaston existence - you would think - WOULD render something more substantial by now if the therapy is legitimate. In addition, I'm fully aware that Burzynski has registered numerous trials - even many dozens which he suspiciously hasn't published the results of - and in the long run you're bound to get flukes. This study could have been a fluke - BUT THE EVIDENCE does NOT suggest that! To fail to mention this study in the kind of article you've written is simply NOT objective analysis and below the kind of objectivity I would expect from Misplaced Pages, which I have donated to more than once in the past and find an invaluable source of information. The fact is sharing these kinds of controlled trial results CANNOT damage humanity - it will all be part of a record that people are entitled to know about, and to FAIL to mention it is just as bad as promoting false information. | |||
::::Again I'm sorry if this sounded rude but direct confrontation of distortion and confusion can often sound rude when its sole purpose is to get closer to accurate representation of the truth. I really hope you consider this further regardless of whatever decision you make and appreciate your time. I'm sorry again for the length of my writing here but I know of no other way to be thorough and as I said before I hope I do not find myself coming back to this repeatedly since I believe the analysis is self-evident and virtually all that I needed to say has been said here, though it be lengthy. ] (]) 04:45, 27 January 2023 (UTC) | |||
:::::See the second sentence of reply to you. - ]the ] 05:48, 27 January 2023 (UTC) | |||
:::::{{tqb|text=many dozens which he suspiciously hasn't published the results of|by=2600:1700:407B:2810:D80F:D35D:F99E:FBCA|ts=04:45, 27 January 2023 (UTC)|id=c-2600:1700:407B:2810:D80F:D35D:F99E:FBCA-20230127044500-Kashmiri-20230122170900}}{{pb}}Check of mine. Burzynski has published a lot more results than the article lets on. Bon courage . (Though just before finishing this comment, I saw some further edits have been made - hope they are a pleasant surprise.) ] (]) 04:42, 17 January 2024 (UTC) | |||
:::Re. the Ogata study, it's all ] – utterly useless for an article about clinical applications. We don't even need to go into the primary vs secondary debate. — ] ] 17:17, 22 January 2023 (UTC) | |||
::::You grossly misrepresented the findings, ignoring the primary endpoint.{{pb}}{{tqb|text=If you insist on including the paper, I'm ok with summarising it along the lines: ''In a 2015 randomised open-label study carried out in Japan, ] was ineffective as an adjuvant therapy for ] resulting from ].''|by=Kashmiri|ts=17:09, 22 January 2023 (UTC)|id=c-Kashmiri-20230122170900-2600:1700:407B:2810:6015:D9D0:4A7D:D0AE-20230122160500}}{{pb}}That's a deceptive summary. You misrepresented the primary endpoint (p=0.037 for CSS) as not statistically significant when it was. {{pb}}You don't want to walk it back, fine. {{pb}}But I'm getting a lot of pushback when I'm removing demonstrably false, defamatory information violating ] that I stumbled upon. ] (]) 04:21, 18 January 2024 (UTC) | |||
:::::As other editors have observed, ] is an poor/unreliable source, and simply not usable here. ] (]) 07:46, 18 January 2024 (UTC) | |||
:::::The Findings section contained | |||
::If I am understand your above post correctly you are leaving the incited chemo/... statement though it has no cite & if I understand correctly, WP does not access the site. I have it from good authority that that is not what they do. | |||
:::::# "Overall survival"- not significant | |||
::The 1st Section of the Burzynski Clinic has: "... but none has been published." Please change to: "which are listed at PubMed.gov." —Didymus Judas Thomas 12/10/12 <small><span class="autosigned">— Preceding ] comment added by ] (] • ]) 11:42, 10 December 2012 (UTC)</span></small><!-- Template:Unsigned --> <!--Autosigned by SineBot--> | |||
:::::# "RFS" - not significant | |||
:::Pretty much false. The studies are listed, but the results are not published. — ] ] 14:11, 10 December 2012 (UTC) | |||
:::::# "CSS rate" - barely significant at 3.7% | |||
:::: Pretty much incorrect: , , , etc. – not mentioning that the entire sentence (in the article) is illogical. <span style="font-family: 'Candara', sans-serif; font-weight: bold; text-shadow: #AAAAFF 0.2em 0.2em 0.1em; class: texhtml">]</span> 14:22, 10 December 2012 (UTC) | |||
:::::# "Cancer recurred" - no statement about significance. | |||
:::::I write this jokingly, but I was hoping WP was not going to put me in the position of having to do additional quoting of additional sites, since if the use goes to the PubMed.gov site, they can follow links to the publications from there; since some of these are published in different publishing sources. Also, I am not sure what you mean about the sentence structure since my request would be to make it: | |||
:::::So, we have the ] - there are four outcomes, one of which is barely significant. Because of multiple comparisons, the significances need to be adapted, making the third one not significant either. But the most relevant finding is obviously the first one, overall survival. (Hint: If the treatment tends to kill the patient as well as the cancer, that is not helpful.) That is the one Kashmiri talked about, and there is nothing wrong with that. Can you please stop trying to cram cherry-picked results into the article? --] (]) 08:01, 18 January 2024 (UTC) | |||
::::::"Some sixty phase 2 clinical trials have been registered by Burzynski since the mid 1990s, and one phase 3 trial, but none has been published. (changed to) | |||
::::::Diffs showing cherry-picked results being crammed into the article? I can't stop doing what I haven't started. Back off with the personal attack, eh? {{pb}}The problem is I'm getting a lot of pushback when I'm removing demonstrably false, defamatory information violating BLP that I stumbled upon. {{pb}}Does MEDRS say anything about the ]? Perhaps it should. {{pb}}But, does V? No. When it comes to BLP violations, ] is what matters. That makes it usable here, even though it's a single study. I notice no one is pushing back on this central point. {{pb}}But more importantly, true or false: Cancer Specific Survival was the SOLE, PRE-selected, primary endpoint, and it DOUBLED. <br>True. Kind of blows apart your whole argument. {{pb}}Kashmiri grossly misrepresented the sole, primary endpoint (p=0.037 for CSS) as not statistically significant when it was. Y'all are defending that. {{pb}}And then K called it basic research - huh? Clinical studies are basic research now? {{pb}}Regarding 3: From the article: <br>{{quote|quote=Nevertheless, the CSS rate was significantly higher in the AN arm versus the control arm (n=33) with a median survival time 67 months (95%CI 43-not calculated) versus 39 months (95%CI 28-47) (p=0.037) and 5 year CSS rate 60% versus 32% respectively.}} so why do you say 3.7%? "3.7" doesn't even appear in the paper! FR! {{pb}}''BTW, the bulk of the shit-ton of negative info about neoplastons in the article is sourced only to non-MEDRS-compliant sources. If I was keen to make neoplastons look better, I could cut most of the negative info out of the article based on MEDRS. How 'bout we compromise, leave all that in, and take out the false info I'm objecting to? '' ] (]) 08:38, 18 January 2024 (UTC) | |||
:::::::"Some sixty phase 2 clinical trials have been registered by Burzynski since the mid 1990s, and one phase 3 trial, which are published here.<ref>http://highwire.stanford.edu/cgi/searchresults?RESULTFORMAT=1&hits=150&sortspec=match&sendit=Update+display&tyear=2013&resourcetype=1&tmonth=Dec&fulltext=Antineoplastons&andorexacttitleabs=and&src=ml&author1=Burzynski&fmonth=Jan&y=0&fyear=1753&x=0&fdatedef=1+January+1753&andorexacttitle=and&searchsubmit=redo&andorexactfulltext=and&tdatedef=3+Dec+2012</ref> | |||
:::::::{{tq|Diffs showing cherry-picked results being crammed into the article?}} Aren't you trying to put what you call "Good Evidence for Antineoplaston Efficacy from Japan" into the article? It is ], so it is cherry-picking. Even if we regard only this study, you are cherry-picking the one significant result out of four. | |||
:::::::Please note the majority of these require payment to read & I only saw 1 free one. | |||
:::::::{{tq|Back off with the personal attack, eh?}} A "personal attack" is something that refers to the person instead of what the person is saying or doing. I referred to what you were saying or doing. That is not a personal attack. | |||
::::::::Also, Burzynski is cited in these publications from 2010 (2) & 2012 & the last 1 from Japan: <ref>http://m.neuro-oncology.oxfordjournals.org/search/keywords/advanced?options=search&options=S.%20Burzynski&options=date&options=Submit&options=10&options=0</ref><ref>http://m.neuro-oncology.oxfordjournals.org/search/keywords/advanced?options=search&options=S.%20Burzynski&options=date&options=Submit&options=10&options=0</ref> <small><span class="autosigned">— Preceding ] comment added by ] (] • ]) 18:09, 10 December 2012 (UTC)</span></small><!-- Template:Unsigned --> <!--Autosigned by SineBot--> | |||
:::::::{{tq|Does MEDRS say anything about the Multiple comparisons problem}} MEDRS does not explicitly mention it, but considering it is part of good practice. If you avoid primary studies like this one, that is a good start avoiding the multiple comparisons problem. | |||
:::::::{{tq|Cancer Specific Survival was the SOLE, PRE-selected, primary endpoint}} Was the "PRE-selected, primary endpoint" published before the result was? I cannot find it. | |||
:::::::{{tq|why do you say 3.7%?}} 3.7% = 0.037. | |||
:::::::{{tq|the bulk of the shit-ton of negative info about neoplastons in the article is sourced only to non-MEDRS-compliant sources}} ] say, {{tq|In an article on a fringe topic, if a notable fringe theory is primarily described by amateurs and self-published texts, verifiable and reliable criticism of the fringe theory need not be published in a peer-reviewed journal.}} --] (]) 10:18, 18 January 2024 (UTC) | |||
::::::::You can't even find a diff showing I called anything "Good Evidence for Antineoplaston Efficacy from Japan," Hob. Or that I tried to put the article you are trying to refer to into the article. So...{{pb}}Your {{tq|Can you please stop trying to cram cherry-picked results into the article?}} when I had done nothing of the sort = false and disparaging but OK, a "not personal" attack, so you're sort of right. ] (]) 13:32, 18 January 2024 (UTC) | |||
:::::::::"Good Evidence for Antineoplaston Efficacy from Japan" is the title of this thread. You are writing contributions to it, and I got the impression that you are supporting the IP that started the thread and trying to get that study cited by the article. | |||
:::::::::So you are not trying to get the Ogata study into the article? Then what are you trying to achieve here by talking about the study? This page is for discussing improvements to the article. It is ]. --] (]) 15:49, 18 January 2024 (UTC) | |||
:::::::::{{Tq|You can't even find a diff showing Or that I tried to put the article you are trying to refer to into the article. So...}} - . ] (]) 18:27, 18 January 2024 (UTC) | |||
=== BLP violation === | |||
:The Burzynski Clinic Article has: | |||
Other investigators have been successful in duplicating some of his results. It's my understanding that ] requires removing the false claim that "other investigators have not been successful in duplicating" any of his results. We all know: Contentious material about living persons that is unsourced or ] '''must be removed immediately''' from the article and its talk page, especially if potentially ]. This is obviously poorly sourced as it is contradicted by ] .gov sources. I've pulled it. If anyone want's to revert, I urge a visit to ] as a next, pre-revert step. ] (]) 04:21, 18 January 2024 (UTC) | |||
::"...a Mayo Clinic study found no benefit...." | |||
::: But that was not what the study concluded. See below: | |||
:.::"CONCLUSION: Although we could not confirm any tumor regression in patients in this study, the small sample size precludes definitive conclusions about treatment efficacy." <ref>www.ncbi.nlm.nih.gov/m/pubmed/10069350</ref> | |||
:::::"Conclusion | |||
Although we could not confirm any tumor regression in patients in this study, the small sample size precludes definitive conclusions about treatment efficacy."<ref>http://www.mayoclinicproceedings.org/article/S0025-6196(11)63835-4/abstract</ref> | |||
:::::::In the interest of Neutrality, please revove the referen e to MYo entirely or change to; | |||
::::::::"...a Mayo Clinic study found that "the small sample size precludes definitive conclusions about treatment efficacy." | |||
:::::::::Thank you very much.] (]) 21:12, 10 December 2012 (UTC)Didymus Judas Thomas 12/10/12 | |||
{{outdent}} | |||
How is "found no benefit" not a a fair and pithy description of the Mayo Clinic study's summary? ] (]) 21:24, 10 December 2012 (UTC) | |||
:I feel this should be changed under WP:NPOV because not every reader is going to understand the "Fair & Pithy" reason I was provided. I feel that the average reader reading this will read it as meaning a study was done & completed with the necessary # of people for an effective study, when that was not the conclusion as pointed out in my above post. Thank you very much.] (]) 11:02, 18 December 2012 (UTC)Didymus Judas Thomas 12/18/12 | |||
:Classic ]. Questions of experimental replication are not biographical; you just need a reliable source saying whether the replication has happened (or not). ] (]) 07:48, 18 January 2024 (UTC) | |||
:In the interest of Neutrality, please add before the pithy Mayo Clinic study reference, after "patients," & before "and": | |||
::"a 1998 study at Kurume University,<ref>http://en.m.wikipedia.org/Kurume_University</ref> School of Medicine, Japan, concluded that "Antineoplastons...exhibit growth inhibition of cancer cells by diverse modes of action. We observed antitumor responses within 2-3 weeks of a combination treatment of chemoradiation therapy and antineoplastons...in phase I clinical study...." "We reviewed 3 clinical cases of advanced cancer...in which we believed antineoplaston A10 and AS2-1 may be contributing to the rapid antitumor response."<ref>www.spandidos-publications.com/or/5/3/597</ref> | |||
:::Thank you very much] (]) 22:04, 10 December 2012 (UTC)Didymus Judas Thomas 12/10/12 | |||
::::That is the first study other than by Burzynski which appears not to have produced a negative result. Perhaps it should receive some mention. For what it's worth, B's publications were before the official end of the studies (all phase 2 trials were still in progress in 2012), so they don't qualify as publication of the results of the studies, only publications about the studies. But, perhaps, something could be done. — ] ] 22:27, 10 December 2012 (UTC) | |||
:In the interest of Neutrality, please add before the fair & pithy Mayo Clinic study reference & my previous 1998 request: | |||
::a 1997 study at Kurume University,<ref>http://en.m.wikipedia.org/Kurume_University</ref> School of Medicine, Japan, concluded that "Antineoplaston AS2-1 exhibits cytostatic growth inhibition of human hepatocellular carcinoma cells in vitro and showed minimum adverse effects in a phase I clinical trial. We reviewed two clinical cases of liver cancer...in whom we believe...Antineoplaston AS2-1 may be effective and useful as a maintenance agent after TAE and MCN in patients." "The two patients...continued to be in good condition for more than two years without limitation of their normal activities."<ref>www.spandidos-publications.com/or/4/6/1213</ref> | |||
:::or consolidate the 1997 & 1998 comments so that the University is not mentioned twice. | |||
::::Thank you very much] (]) 23:11, 10 December 2012 (UTC)Didymus Judas Thomas 12/10/12 | |||
:and please add "another 1998 study stated" | |||
::"Antineoplaston A10 injection...exhibited cystostatic growth inhibition of human hepatocellular carcinoma...cells in vitro and showed minimum adverse effects in a phase I clinical trial." In "2 cases of advanced HCC treated with antineoplaston A10 I....oth cases showed interesting responses to antineoplaston A10 I. One showed massive coagulation necrosis of tumors after intra-arterial infusion of antineoplaston A10 I and the other showed resolution of portal vein tumor thrombosis with systemic infusion of antineoplaston A10 I. <ref>http://www.spandidos-publications.com/or/5/6/1363</ref> | |||
:::Thank you very much] (]) 23:38, 10 December 2012 (UTC)Didymus Judas Thomas 12/10/12 | |||
In the interest of Neutrality, please add after the Mayo study: | |||
::"a 2002 study stated that" | |||
"Antineoplastons are naturally occurring peptides and amino acid derivatives that control neoplastic growth. Antineoplaston A10 and AS2-1 are chemically identified and synthesized antineoplastons proven to inhibit cancer cell growth by arresting the cell cycle in the G1 phase and inhibiting tumor growth by reducing mitosis. These agents are thought to be good candidates for clinically easily applicable non-toxic p53 gene activators. Our cases of advanced cancer responded well to combination treatment using chemotherapeutics and irradiation with antineoplaston A10 and AS2-1 in clinical trials being conducted..."<ref>www.spandidos-publications.com/or/9/1/65</ref> | |||
:::Thank you very much] (]) 23:55, 10 December 2012 (UTC)Didymus Judas Thomas 12/10/12 | |||
:In the interest of Neutrality, please add after the 2002 study: | |||
::"in 2003, at Kurume Daiichi Social Insurance Hospital," | |||
:::"We designed a phase II clinical trial..." "Ten patients were enrolled in this trial, 2 in stage I, 6 in stage II, 1 in stage III, 1 in stage IV-B at initial diagnosis. Ten patients experienced 35 recurrence-free intervals. Recurrence-free intervals during antineoplaston AS2-1 administration were significantly longer than those without antineoplaston AS2-1." "Patients who experienced recurrence-free intervals with and without antineoplaston AS2-1 showed longer intervals during antineoplaston AS2-1 administration than those before and after antineoplaston AS2-1 administration Two patients in stage I showed longer recurrence-free intervals than those in more advanced stages. "ntineoplaston AS2-1...prolonged the recurrence-free interval between regional treatments and improved survival rate of these patients."<ref>www.spandidos-publications.com/or/9/1/65</ref> | |||
::::Thank you very much] (]) 00:55, 11 December 2012 (UTC)Didymus Judas Thomas 12/10/12 | |||
:In the interest of Neutrality, please add after the 2003 study: I requested be added: | |||
::"in 2005 a study showed that" | |||
:::"Antineoplaston...AS2-1 inhibited KM12SM cell proliferation through G1 cell arrest and, at a higher concentration, induction of apoptosis...showed significant reduction in lung metastasis at 5 weeks after cecal removal. The survival rate in the...group was significantly higher than that in the control..." and "showed an antimetastatic effect against post-operative lung metastases from colon cancer through G1 cell arrest and the subsequent induction of apoptosis."<ref>www.spandidos-publications.com/or/13/3/389 | |||
</ref> | |||
::::Thank you very much] (]) 01:00, 11 December 2012 (UTC)Didymus Judas Thomas 12/10/12 | |||
:In the interest of Neutrality, please add after the other 2005 study I requested be added: | |||
::"Another 2005 study showed that" | |||
:::"Antineoplastons such as A10 include naturally occurring peptides and amino acid derivatives that control the neoplastic growth of cells." "Our findings indicate that the antineoplaston A10 antitumor effect could be utilized as an effective therapy for breast cancer patients.<ref>http://www.spandidos-publications.com/or/14/2/489</ref> | |||
::::Thank you very much] (]) 01:22, 11 December 2012 (UTC)Didymus Judas Thomas 12/10/12 | |||
:I oppose the addition of any primary studies that are not discussed in a secondary source, per ], ] and ]. ] (]) 01:30, 11 December 2012 (UTC) | |||
::I agree, for all the same reasons. ] (]) 04:46, 11 December 2012 (UTC) | |||
::::I disagree as the above 2 request cite no evidence that either poster reviewed any of the cites to support the claim that these cites are not discussed in a secondary source (see below): | |||
:::::http://www.ncbi.nlm.nih.gov/m/pubmed/9769368 (141 cites) | |||
:::::http://www.ncbi.nlm.nih.gov/m/pubmed/15706406 (125 cites) | |||
:::::http://www.ncbi.nlm.nih.gov/m/pubmed/16012735 (109 cites) ] (]) 21:38, 12 December 2012 (UTC)Didymus Judas Thomas 12/12/12 | |||
:Please add after "''Italic text''antineoplastons" link <ref>http://www.cancer.gov/cancertopics/pdq/cam/antineoplastons/healthprofessional/page1</ref> as this National Cancer Institute, at the National Institutes of Health link provides valuable information re Antineoplastons] (]) 20:39, 12 December 2012 (UTC)Didymus Judas Thomas 12/12/12 | |||
== Oddly, I can't find an NIH publication. == | |||
:Please remove "but none has been published." in re Burzynski's clinical trials as I have shown in my request for a Phase I section to be added. Thank you very much.] (]) 21:38, 12 December 2012 (UTC)Didymus Judas Thomas 12/12/12 | |||
A footnote in a journal article on the Phase III trial that the wipedia article uses as a source: <ref name=HammerICT>{{cite journal|last1=Hammer|first1=Mitchell R.|last2=Jonas|first2=Wayne B.|title=Managing Social Conflict in Complementary and Alternative Medicine Research: The Case of Antineoplastons|journal=Integrative Cancer Therapies|date=March 2004|volume=3|issue=1|pages=59–65|doi=10.1177/1534735404263448|pmid=15035877|doi-access=free}}</ref><br> | |||
:Please remove: | |||
is {{quote|§ See M. R. Hammer, Burzynski antineoplaston case study: conflict issues and recommendations. Office of Alternative Medicine report, '''National Institutes of Health''', 1996; M. Hammer, The management of dispute and judgment process in controversial complementary and alternative medicine research. Office of Alternative Medicine Report, National Institutes of Health, 1996.}}<br> | |||
::"There is no conclusive evidence to support the antineoplaston theory." | |||
Has anyone found a copy of it anywhere online? I can't with google. | |||
:::"No conclusive evidence" has no source. It is also Not true. FDA wouldn't have given permission for Phase 3 trials if this were true. | |||
:::: http://www.sec.gov/Archives/edgar/data/724445/000110465909002283/a09- | |||
:::::Thank you very much.] (]) 22:17, 12 December 2012 (UTC)Didymus Judas Thomas 12/12/12 | |||
The article is by Hammer and he is citing his own work ... which I can't find. Curious. Also, he doesn't put it in the References section endnote like all his other sources, but rather in a footnote. Also curious. The resulting procedures - methods of social management of research in controversial areas to allow them to proceed anyway that the reference documents haven't been employed in a subsequent second attempt. Curious as well. ] (]) 04:24, 17 January 2024 (UTC) | |||
* You appear to be taking extreme liberties with the number of citations you claim the papers have received. The one you claimed as "141 cites" appears to have maybe 3 for example, and it's an in vitro study (I don't have access to the full paper, just the summary). ] (]) 22:49, 12 December 2012 (UTC) | |||
{{Reflist-talk}} | |||
:WWayne Jonas should not be cited, he's a quackery apologist (e.g. author of a number of papers promoting the entirely refuted nonsense that is homeopathy). ''']''' <small>(] - ])</small> 19:39, 17 January 2024 (UTC) | |||
:IRWolfie, not quite sure what you mean since when I accessed those links, for example, & scroll down to the bottom where it has "Related Citations," & I select the "Show all" option, that's the # of cites those brought up.] (]),Didymus Judas Thomas 12/14/12 <span style="font-size: smaller;" class="autosigned">—Preceding ] comment added 08:00, 14 December 2012 (UTC)</span><!--Template:Undated--> <!--Autosigned by SineBot--> | |||
::Huh? I am not looking for or seeking to cite "WWayne Jonas" <sic> work in the encyclopedia. And given your recent dubious evaluation of what is "excellent", I'm less interested in what you are sharing, un-prompted and citation-free. I'm looking for M. R. Hammer's '''1996 NIH''' publication, not Hammer and Jonas' 2004 ICT publication, which is obviously readily available at the linked source I provided - <ref name=HammerICT>. Do you have anything helpful to offer about what I'm actually expressing curiosity? ] (]) 02:36, 18 January 2024 (UTC) | |||
:::You kind've are. Wayne Jonas was director of the Office of Alternative Medicine at the time. The OAM (now the NCCIH) is independent from the rest of the NIH, so you probably won't find their reports in the same places as the rest of the NIH's output. It wouldn't be usable on Misplaced Pages anyway. ] (]) 02:52, 18 January 2024 (UTC) | |||
::::Thanks for the info. Why wouldn't it be usable with subject matter where MEDRS doesn't apply? ] (]) 04:07, 18 January 2024 (UTC) | |||
::::: ], you wrote: "I am not looking for or citing "WWayne Jonas" <sic> work." Actually you are. Jonas is one of the authors of "Managing Social Conflict in Complementary and Alternative Medicine Research: The Case of Antineoplastons". Mitchell R. Hammer, PhD, and Wayne B. Jonas, MD | |||
::::: So Jonas is one of the authors, and, as noted above by ], he also happens to be a promotor of quack medicine. -- ] (]) (''''']''''') 05:46, 18 January 2024 (UTC) | |||
:::::I would be amazed if you got consensus that a report from the OAM is RS even in non medical contexts, let alone for Burzynski-related stuff. The OAM was set up in the first place because Sen. ] was a believer (specifically in antineoplastons and bee pollen therapy) and he set the office up and kept it funded to promote those treatments. The whole thing is a political exercise that has very little to do with science. ] (]) 18:33, 18 January 2024 (UTC) | |||
::::::{{pullquote|quote=If I say 1996+2=2004, then 1996+2=2004.}}- O'Brien ] (]) 07:20, 18 January 2024 (UTC) | |||
== Questionable ] source == | |||
::Related citations are just articles which the search engine thinks might be related. It is not a measure of the impact of the article, nor of the number of citations. ] (]) 12:50, 14 December 2012 (UTC) | |||
The source https://pubmed.ncbi.nlm.nih.gov/3527634/ should really not be used for anything like a factual claim, as it's ABOUTSELF material - Burzynski's own self-serving statement, with no objective review, and including contentious and likely tendentious claims like "The treatment was free from significant side-effects and resulted in objective response in a number of advanced cancer cases". After half a century, there should be an independent source for this, and almost certainly would be, if it were objectively true. ''']''' <small>(] - ])</small> 19:38, 17 January 2024 (UTC) | |||
Please add: | |||
"Research and clinical studies on antineoplastons have been conducted in Japan since 1988<ref>http://assets0.pubget.com/paper/7474850/The_effect_of_Antineoplaston__a_new_antitumor_agent_on_malignant_brain_tumors </ref> <ref>http://assets0.pubget.com/paper/8755117/Inhibitory_effect_of_antineoplaston_A10_and_AS2_1_on_human_hepatocellular_carcinoma </ref> and successful Phase I Clinical Trials have been done starting in 1994 on Antineoplastons A5<ref>http://assets0.pubget.com/paper/7813388/The_influence_of_antineoplaston_A5_on_the_central_dopaminergic_structures </ref>, A10 & AS2-1, <ref>http://assets0.pubget.com/paper/21590224/Antineoplaston_AS2_1_for_maintenance_therapy_in_liver_cancer </ref><ref>http://assets0.pubget.com/paper/9538158/Quick_response_of_advanced_cancer_to_chemoradiation_therapy_with_antineoplastons </ref><ref>http://assets0.pubget.com/paper/11748457/A_novel_strategy_for_remission_induction_and_maintenance_in_cancer_therapy </ref> and A101."<ref>http://assets0.pubget.com/paper/9769368/Antineoplaston_treatment_for_advanced_hepatocellular_carcinoma </ref> | |||
Thank you very much] (]) 09:13, 16 December 2012 (UTC). | |||
== Claim of copyright violation == | |||
:These are primary sources. --] (]) 11:39, 16 December 2012 (UTC) | |||
::Indeed. This has been discussed here in the past. The issue is covered under ] and ]. Primary sources, like phase I and II clinical trials, are always trumped by secondary sources and must never be used to contradict scientific consensus. This has already been addressed on the Talk page in the past and need not be re-litigated. ---- | |||
:::Below are links for Burzynski Phase II Clinical Trials which consist of the (1) link I initially provided, (2) PubMed link, (3) actual publication link, (4) link re cites, & (5) cancer . gov link at the end: | |||
:::<ref> http://assets0.pubget.com/paper/16484713/Targeted_therapy_with_antineoplastons_A10_and_AS2_1_of_high_grade__recurrent__and_progressive_brainstem_glioma </ref> | |||
<ref> http://www.ncbi.nlm.nih.gov/m/pubmed/16484713 </ref> <ref> http://ict.sagepub.com/content/5/1/40.abstract </ref> <ref> http://scholar.google.com/scholar?hl=en&lr=&cites=11294308654191112940&um=1&ie=UTF-8&sa=X&ei=09LXUJi2DYWm9gTK4oHACg&ved=0CDcQzgIwAjgU </ref> <ref> http://assets0.pubget.com/paper/15911929/Long_term_survival_of_high_risk_pediatric_patients_with_primitive_neuroectodermal_tumors_treated_with_antineoplastons_A10_and_AS2_1 </ref> <ref> http://www.ncbi.nlm.nih.gov/m/pubmed/15911929 </ref> <ref> http://ict.sagepub.com/content/4/2/168.abstract </ref> <ref> http://scholar.google.com/scholar?hl=en&lr=&cites=8290359870590320314&um=1&ie=UTF-8&sa=X&ei=H9bXUKbJD4fK9QSqnIC4Aw&ved=0CC4QzgIwAA </ref> <ref> http://assets0.pubget.com/paper/15563234/Phase_II_study_of_antineoplaston_A10_and_AS2_1_in_children_with_recurrent_and_progressive_multicentric_glioma___a_preliminary_report </ref> <ref> http://www.ncbi.nlm.nih.gov/m/pubmed/15563234 </ref> <ref> http://adisonline.com/drugsrd/pages/articleviewer.aspx?mobile=0&year=2004&issue=05060&article=00002&type=Abstract&desktopMode=true </ref> <ref> http://assets0.pubget.com/paper/15312271/Long_term_survival_and_complete_response_of_a_patient_with_recurrent_diffuse_intrinsic_brain_stem_glioblastoma_multiforme </ref> <ref> http://www.ncbi.nlm.nih.gov/m/pubmed/15312271 </ref> <ref> http://ict.sagepub.com/content/3/3/257.abstract </ref> <ref> http://scholar.google.com/scholar?hl=en&lr=&cites=16430209596015133070&um=1&ie=UTF-8&sa=X&ei=YdjXUKHzL4309gTR1oCAAw&ved=0CC4QzgIwAA </ref> <ref> http://assets0.pubget.com/paper/15035876/The_present_state_of_antineoplaston_research__1_ </ref> <ref> http://www.ncbi.nlm.nih.gov/m/pubmed/15035876 </ref> <ref> http://ict.sagepub.com/content/3/1/47.abstract </ref> <ref> http://scholar.google.com/scholar?hl=en&lr=&cites=4876326067599057463&um=1&ie=UTF-8&sa=X&ei=EtXXUOfTKora8ASx84CoBw&ved=0CC4QzgIwAA </ref> <ref> http://assets0.pubget.com/paper/12718563/Phase_II_study_of_antineoplaston_A10_and_AS2_1_in_patients_with_recurrent_diffuse_intrinsic_brain_stem_glioma__a_preliminary_report </ref> <ref> http://www.ncbi.nlm.nih.gov/m/pubmed/12718563 </ref> <ref> http://adisonline.com/drugsrd/pages/articleviewer.aspx?mobile=0&year=2003&issue=04020&article=00002&type=Abstract&desktopMode=true </ref> <ref> http://scholar.google.com/scholar?hl=en&lr=&cites=2463317484923053692&um=1&ie=UTF-8&sa=X&ei=xtnXUKyHOoX28wSy-ICwCQ&ved=0CC4QzgIwAA </ref> <ref> | |||
http://www.cancer.gov/cancertopics/pdq/cam/antineoplastons/healthprofessional/page5 </ref> | |||
:::Thank you very much.] (]) 04:34, 24 December 2012 (UTC)Didymus Judas Thomas 12/23/2012 | |||
The wording is a bit close, but it is a paraphrase. Rather than deleting it, suggest a reword. ] (]) 02:59, 18 January 2024 (UTC) | |||
* It's like this. Burzynski has registered 60 Phase II and one Phase III trial with ]. Not one of the phase II trials has been published and the phase III trial has yet to accrue a single patient. Like it or not, ANPs are firmly linked to Burzynski personally, and the major problem has always been ''his'' failure to produce any compelling evidence. We don't go wading through primary sources such as those you list, instead we refer to secondary sources. These are, as far as I can tell, in unanimous agreement that Burzynski's treatment is unproven and of little evident promise. We have the American Cancer Society, Cancer Research UK, Memorial Sloan-Kettering, the FDA and numerous other sources for exactly that and no reliable independent secondary source for any promising outcome. We are told that 2013 will be a big year, but apparently his plan is to release another bullshit movie not to publish useful research. <b>]</b> <small>(])</small> 21:52, 24 December 2012 (UTC) | |||
:False. It's not a paraphrase. It's copying by JzG contrary to a Misplaced Pages policy with legal considerations. ] / ]. ] (]) 04:13, 18 January 2024 (UTC) | |||
::JzG, I'm not sure what relevance your above comments have re WP: NPOV. Burzynski's Phase I & II Clinical Trial data has been published as indicated on cancer . gov National Cancer Institute, at the National Institutes of Health, as indicated on the Antineoplastons: Human/Clinical Trials page where it states: "Publications have taken the form of case reports, phase I clinical trials, toxicity studies, and phase II clinical trials." | |||
:: It's called plagiarism. Putting it in quotes and attributing it solved the problem. -- ] (]) (''''']''''') 07:17, 18 January 2024 (UTC) | |||
::Additionally, it then states: "Table 2 summarizes the following clinical trials and appears at the end of this section." | |||
:Now it's more messed up. ''a cancer expert and an FDA official told Reuters'' and ''Reuters said'' aren't the same. ] (]) 04:40, 18 January 2024 (UTC) | |||
::It then cites, at the bottom of the page," References" for Burzynski's Phase I & II Clinical Trial publications. | |||
::Well, perhaps you should have left well alone, then, since your clumsy attempt to fix the “problem” of reality rejecting Burzynski’s piss therapy seems to be the root cause of all this drama. ''']''' <small>(] - ])</small> 09:06, 22 January 2024 (UTC) | |||
::Above I included Secondary Sources as indicated in "(4) link re cites," which consist of 8, 11, 4, 6, 16, & 19 Secondary Source references respectively. | |||
::Additionally, below are links for Burzynski's Phase I Clinical Trials which consist of the (1) link I initially provided, (2) PubMed link, (3) link re cites, & (4) cancer . gov link at the end, where (3) = 16, 7, 23, & 29 Secondary Source references respectively: | |||
::<ref> http://assets0.pubget.com/paper/3569014/Phase_I_clinical_studies_of_antineoplaston_A5_injections </ref> <ref> http://www.ncbi.nlm.nih.gov/m/pubmed/3569014 </ref> <ref> http://scholar.google.com/scholar?hl=en&lr=&cites=3511838269820484232&um=1&ie=UTF-8&sa=X&ei=0-LZUImsCKfV0gHAi4G4CA&ved=0CDMQzgIwAA </ref> <ref> http://assets0.pubget.com/paper/3569012/Phase_I_clinical_studies_of_antineoplaston_A3_injections </ref> <ref> http://www.ncbi.nlm.nih.gov/m/pubmed/3569012 </ref> <ref> http://scholar.google.com/scholar?hl=en&lr=&q=related:tw1ySRfqzF4J:scholar.google.com/&um=1&ie=UTF-8&sa=X&ei=cuPZUO-tL4fe8wSUn4DgCQ&ved=0CDQQzwIwAA </ref> <ref> http://assets0.pubget.com/paper/3569010/Initial_clinical_study_with_antineoplaston_A2_injections_in_cancer_patients_with_five_years__follow_up </ref> <ref> http://www.ncbi.nlm.nih.gov/m/pubmed/3569010 </ref> <ref> http://scholar.google.com/scholar?hl=en&lr=&cites=12205002420988089654&um=1&ie=UTF-8&sa=X&ei=2-PZUIPMBYqY8gTHsYH4CA&ved=0CC4QzgIwAA </ref> <ref> http://assets0.pubget.com/paper/3527634/Antineoplastons__history_of_the_research__I_ </ref> <ref> http://www.ncbi.nlm.nih.gov/m/pubmed/3527634 </ref> <ref> http://scholar.google.com/scholar?hl=en&lr=&cites=17108574720320274953&um=1&ie=UTF-8&sa=X&ei=jBPaUIP1LYT49QTHsYHAAw&ved=0CDEQzgIwAA </ref> <ref> http://www.cancer.gov/cancertopics/pdq/cam/antineoplastons/healthprofessional/page3 </ref> | |||
::Additionally, below are links for Japanese Phase I Clinical Trials which consist of the (1) link I initially provided, (2) PubMed link, (3) actual publication link, (4) link re cites, & (5) cancer . gov link at the end, the (4) consisting of 15, 12, 11, & 2 Secondary Source references respectively: | |||
::<ref> http://pubget.com/paper/11748457/A_novel_strategy_for_remission_induction_and_maintenance_in_cancer_therapy </ref> <ref> http://www.ncbi.nlm.nih.gov/m/pubmed/11748457 </ref> <ref> http://www.spandidos-publications.com/or/9/1/65 </ref> <ref> http://scholar.google.com/scholar?hl=en&lr=&cites=8768810707715376780&um=1&ie=UTF-8&sa=X&ei=ZVrZUL3HK4L09gT-r4GIBg&ved=0CC0QzgIwAA </ref> <ref> http://assets0.pubget.com/paper/9769368/Antineoplaston_treatment_for_advanced_hepatocellular_carcinoma </ref> <ref> http://www.ncbi.nlm.nih.gov/m/pubmed/9769368 </ref> <ref> http://www.spandidos-publications.com/or/5/6/1363 </ref> <ref> | |||
http://scholar.google.com/scholar?hl=en&lr=&cites=10510638756255752003&um=1&ie=UTF-8&sa=X&ei=nlvZUPnRNoKy8ASpzYFI&ved=0CDcQzgIwAA </ref> <ref> http://assets0.pubget.com/paper/9538158/Quick_response_of_advanced_cancer_to_chemoradiation_therapy_with_antineoplastons </ref> <ref> http://www.ncbi.nlm.nih.gov/m/pubmed/9538158 </ref> <ref> www.spandidos-publications.com/or/5/3/597 </ref> <ref> http://scholar.google.com/scholar?hl=en&lr=&cites=15160515052055359089&um=1&ie=UTF-8&sa=X&ei=eFzZULr3O4fc8wSx14CgBQ&ved=0CDUQzgIwAA </ref> <ref> | |||
http://assets0.pubget.com/paper/21590224/Antineoplaston_AS2_1_for_maintenance_therapy_in_liver_cancer </ref> <ref> | |||
http://www.ncbi.nlm.nih.gov/m/pubmed/21590224 </ref> <ref> http://www.spandidos-publications.com/or/4/6/1213 </ref> <ref> http://scholar.google.com/scholar?hl=en&lr=&cites=18425011917240905819&um=1&ie=UTF-8&sa=X&ei=HF3ZUOmaNYL48wSqhIHYAg&ved=0CDQQzgIwAA </ref> <ref>http://www.cancer.gov/cancertopics/pdq/cam/antineoplastons/healthprofessional/page5 </ref> | |||
::I think it's premature to state that no Antineoplaston research is ongoing in China, Japan, or Egypt, since publications have been done up to 2009 & Burzynski has published re ongoing work which includes this year. Thank you very much.] (]) 21:51, 25 December 2012 (UTC)Didymus Judas Thomas 12/25/2012 | |||
::: What you are doing is presenting a ]. The consensus of reliable independent secondary sources is that ANPs are promoted primarily by Burzynski, that his science is far form rigorous, and that they do not represent a particularly hopeful line of inquiry. And that's before you get to the outright lies told by Burzynski and his supporters, e.g. that it is "non-toxic" and "not chemotherapy", routinely claiming that tumours which have outgrown their blood supply are being cured by ANPs (these patients usually die shortly afterwards) and so on. There is unlikely to be any dispassionate debate over ANPs while Burzynski continues with his unethical practices. <b>]</b> <small>(])</small> 12:43, 26 December 2012 (UTC) | |||
::::JzGIGuy, I'm not sure what relevance your above post has to do with WP:NPOV since the independent Japanese Phase I & II clinical trials are actual Clinical Trials as opposed to opinion, conjecture, theory, etc. | |||
;;;;Please add per WP:NPOV that a Japanese Phase II Clinical Trial which consist of the (1) PubMed link & (2) link re cites, the (2) consisting of 9 Secondary Source references; in order to show independent trials show success: | |||
"A Phase II clinical trial in Japan of 10 patients; 2 in stage I, 6 in stage II, 1 in stage III, 1 in stage IV-B, experienced 35 recurrence-free intervals during antineoplaston AS2-1 administration, which were significantly longer than those without antineoplaston AS2-1" | |||
<ref> http://www.ncbi.nlm.nih.gov/m/pubmed/12579278 </ref> <ref> http://scholar.google.com/scholar?hl=en&lr=&cites=3611231307540428029&um=1&ie=UTF-8&sa=X&ei=GIDcUKLGLYHC9QTxjYG4BA&ved=0CC4QzgIwAA </ref> | |||
Thank you very much.] (]) 17:44, 27 December 2012 (UTC)Didymus Judas Thomas 12/27/2012 | |||
:If you read ] you should come to realize that continuing to post links to these primary source phase I and II trials is a wasted effort. What matters is what reliable secondary sources have said about the research as a whole. ] (]) 22:30, 27 December 2012 (UTC) | |||
:: Why? ] says explicitly that primary sources ''are'' allowed on Misplaced Pages if used "with care". The above-listed reports of clinical trials have not (yet) been summarised in a reliable secondary source; hence, in order not to skip valid information in this article, one has to resort to quoting primary sources. Sure, it has to be done very carefully and without jumping to conclusions that do not exist in these articles. But repeat: primary sources ''are'' allowed as per ]. <span style="font-family: 'Candara', sans-serif; font-weight: bold; text-shadow: #AAAAFF 0.2em 0.2em 0.1em; class: texhtml">]</span> 23:16, 27 December 2012 (UTC) | |||
:::The wording is "reliable primary sources may occasionally be used with care '''as an adjunct to the secondary literature'''" (my emphasis). Which is a bit different. ] (]) 05:22, 28 December 2012 (UTC) | |||
::::RIR, thank you for your above post pointing out that I was wasting my time posting Primary Sources. Please note that my above post mentions Secondary Sources I provided. Below is a specific Secondary Source from that Google Scholar Link for Burzynski's 2006 Phase II trial, from the: Japanese Journal of Clinical Oncology (2008) <ref> http://jjco.oxfordjournals.org/content/38/8/512.full?sid=363c7cc9-7b16-48d2-ae4c-d9828da57a46 </ref> Thank you very much.] (]) 06:25, 28 December 2012 (UTC)Didymus Judas Thomas 12/28/2012 | |||
::::RIR, thank you for your above post re Primary Sources. Please note that my above post mentions Secondary Sources I provided. Below is a specific Secondary Source from that Google Scholar Link for Burzynski's 2005 Phase II trial, from the Journal: Cancer (2012) <ref> http://onlinelibrary.wiley.com/doi/10.1002/cncr.26300/full </ref> Thank you very much.] (]) 06:58, 28 December 2012 (UTC)Didymus Judas Thomas 12/28/2012 | |||
::::RIR, thank you for your above post re Primary Sources. Please note that my above post mentions Secondary Sources I provided. Below is a specific Secondary Source from that Google Scholar Link for Burzynski's 2004 Phase II trial, from the Journal: Chemical Research in Chinese Universities (3/2006) <ref> http://www.sciencedirect.com/science/article/pii/S1005904006600846 </ref> Thank you very much.] (]) 07:40, 28 December 2012 (UTC)Didymus Judas Thomas 12/28/2012 | |||
::::RIR, thank you for your above post re Primary Sources. Please note that my above post mentions Secondary Sources I provided. Below is a specific Secondary Source from that Google Scholar Link for Burzynski's 9/2004 Phase II trial, from the: Canadian Journal of Neurosciences (8/2007) <ref> http://cjns.metapress.com/content/w76m361214p67r64 </ref> Thank you very much.] (]) 08:24, 28 December 2012 (UTC)Didymus Judas Thomas 12/28/2012 | |||
== Talk page vandalism. == | |||
:::::I've just checked the last two sources and ''neither one is a secondary source'', and as far as I can tell neither discusses Burzynski. | |||
:::::"Chemical research in Chinese Universities (3/2006)" is entitled ''Expression of RNA Editing Deaminase on Human Glioma Cell Lines'' and, as the title tells us, is a study on cell lines. ADAR2 and ADAR3 are not "antineoplastons", they're enzymes that our body produces. I don't have access to the full text, but the abstract doesn't make it look like Burzynski is more than one of various citations. | |||
:::::"Canadian Journal of Neurosciences (8/2007)" is entitled ''Coincidence vs Cause: Cure in Three Glioblastoma Patients Treated with Brachytherapy'' - ] is a form of radiotherapy. It only uses Burzynski as a citation for the following statement: "Very long term survival after glioblastoma has been described in individual cases" - we know that Burzynski has described such cases, but (very much like this source, which concluded that while there were 3 long term survivors in the treatment (brachytherapy) group versus no long term survivors in the control group it was unlikely that the longer survival was due to the treatment) he hasn't shown that the treatment helped them survive. | |||
:::::You don't seem to understand what a ] is. It's not any study that cites another source, it's a study that evaluates and combines multiple sources to see if their individual outcomes are due to a real effect or likely just chance findings. A ] is a secondary source. A ] is a secondary source. The articles above aren't. | |||
:::::A secondary source for Burzynski's treatment would be an independend review or meta-analysis of his studies, or of the studies using his treatment finding that they are effective - I have searched pubmed for such a source but haven't found one. --] (]) 09:51, 28 December 2012 (UTC) | |||
::::::Six words, thank you for suggesting that I "don't seem to understand what a secondary source is." ] references: "Ideal sources for biomedical material include general or systematic reviews in reliable, third-party, published sources, such as reputable medical journals...", "Ideal sources for such content includes general or systematic reviews published in reputable medical journals, ...", "A secondary source in medicine summarizes one or more primary or secondary sources, usually to provide an overview of the current understanding of a medical topic, to make recommendations, or to combine the results of several studies. Examples include literature reviews or systematic reviews found in medical journals, ...", "Reliable primary sources may occasionally be used with care as an adjunct to the secondary literature, ..." & "If the conclusions of the research are worth mentioning, they should be described as being from a single study, for example: "A 2009 U.S. study found the average age of formal autism spectrum diagnosis was 5.7 years." (citing PMID ________)"" Maybe your definition of "general review," or "summarizes" in a Secondary Third-Party Source medical journal is different than mine. The Chinese research cites much of the same terminology Burzynski uses re glioma & is cite .] (]) 18:52, 28 December 2012 (UTC)Didymus Judas Thomas 12/28/2012 | |||
:::::::Oh, you're welcome. Great copy pasta, now you only need to start understanding what these statements mean. Even if it was OK to use this study (you know what occasionally, with great care, as an adjunct means, right?), there'd still be one little problem: this study is '''isn't about "antineoplaston treatment"'''. --] (]) 19:12, 28 December 2012 (UTC) | |||
::::::::Six words, I see nothing that indicates that the medical journal review has to be about "antineoplaston treatment". ] "A secondary source in medicine summarizes one or more primary or secondary sources, ... to combine the results of several studies." It does not indicate that the review can't combine the results of several studies about different forms of Cancer treatment.] (]) 20:46, 28 December 2012 (UTC)Didymus Judas Thomas 12/28/2012 | |||
Beware removing active discussion. ] (]) 06:49, 18 January 2024 (UTC) | |||
:::::::::Since you cited a passage that says (I paraphrase) 'under very special circumstances primary sources may be admissible' I thought you understood that these sources are ''primary sources'' - if you don't understand it, there's no point to continue this discussion, as I won't be checking new "secondary" sources you provide until you're able to tell apart primary and secondary sources. And ''of course'' a study needs to deal with the "antineoplaston treatment" if you want to claim it supports this treatment. Everything else would be ]. --] (]) 21:27, 28 December 2012 (UTC) | |||
: Now a third time. I was archiving old and inactive content and didn't notice you had left comments in some of them. Now you have restored the whole thing. I'll be more careful with the next try. -- ] (]) (''''']''''') 07:07, 18 January 2024 (UTC) | |||
: To avoid this in the future, don't comment on such old threads. Start a new thread. -- ] (]) (''''']''''') 07:14, 18 January 2024 (UTC) | |||
As Six words pointed out, the articles listed above by Didymus are primary sources, not secondary (see Definitions under ]. ] addresses the broader issue raised by Didymus quite clearly: | |||
::Thank you! Such helpful advice. SO kind of you. ] (]) 07:21, 18 January 2024 (UTC) | |||
== Notice == | |||
:"Individual primary sources should not be cited or juxtaposed so as to "debunk" or contradict the conclusions of reliable secondary sources...primary sources favoring a minority opinion should not be aggregated or presented devoid of context in such a way as to undermine proportionate representation of expert opinion in a field...If the findings involve phase I or phase II clinical trials...then these findings are probably only indirectly relevant to understanding human health; in these cases, they should be entirely omitted...When in doubt, omit mention of the primary study...because determining the weight to give to such a study requires reliable secondary sources." ] (]) 16:36, 28 December 2012 (UTC) | |||
::RIR, the following are irrelevant: (1) American Cancer Society &(2) Cancer Research UK, are both Private organizations with nothing re Antineoplastons on PubMed & their motivation can be questioned as Competitors of Burzynski. (3) Memorial Sloan-Kettering has 1 PubMed article re Antineoplastons but are also a Private organization whose motivation can also be questioned as a Competitor of Burzynski. (4) The FDA's opinion is also irrelevant since Phase II studies were promising enough for them to authorize Phase III Clinical Trials re Antineoplastons. Additional, the Mayo Clinic study in this article had the "CONCLUSION: Although we could not confirm any tumor regression in patients in this study, the small sample size precludes definitive conclusions about treatment efficacy. ..." <ref> www.ncbi.nlm.nih.gov/m/pubmed/10069350 </ref> & the NIH Phase II Clinical Trials were reported in 2004 – "Managing social conflict in complementary and alternative medicine research: the case of antineoplastons," "hese studies were stopped before it was possible to determine the effectiveness of antineoplastons." "o determine why this study failed to be completed," there was "a detailed analysis of the conflicts that led to the study's closure. The intent was to understand the social dynamics surrounding this failed study" <ref> http://www.ncbi.nlm.nih.gov/m/pubmed/15035877 </ref> Are you indicating that the following medical journals are not medical journals within the meaning of Secondary Third-Party resources? (A) Japanese Journal of Clinical Oncology, (B) Cancer, (C) Chemical Research in Chinese Universities, & (D) Canadian Journal of Neurosciences?] (]) 21:24, 28 December 2012 (UTC)Didymus Judas Thomas 12/28/2012 | |||
{{t|BLP noticeboard}} ] (]) 09:05, 18 January 2024 (UTC) | |||
*Please add, to dispute "that antineoplaston therapy is" ... "of little promise in treating cancer." | |||
"In 2002 Japanese clinical trials, cases of advanced cancer responded well to combination treatment using antineoplastons A10 and AS2-1, proven to inhibit cancer cell growth and tumor growth." <ref> http://www.ncbi.nlm.nih.gov/m/pubmed/11748457 </ref> | |||
*Citing Secondary Source Medical Journals: Oncology reports (8/2005) <ref> http://www.spandidos-publications.com/or/14/2/489 </ref> Integrative Cancer Therapies (3/2004) <ref> http://ict.sagepub.com/content/3/1/47.abstract </ref> Journal of Chemical Research (12/1/2003) <ref> http://www.ingentaconnect.com/content/stl/jcr/2003/00002003/00000012/art00016 </ref> & Medical Hypotheses (4/2003) <ref> http://www.sciencedirect.com/science/article/pii/S0306987703000501 </ref> Thank you very much.04:20, 29 December 2012 (UTC)Didymus Judas Thomas 12/28/2012 <small><span class="autosigned">— Preceding ] comment added by ] (] • ]) </span></small><!-- Template:Unsigned --> <!--Autosigned by SineBot--> | |||
*Please add, to dispute "that antineoplaston therapy is" ... "of little promise in treating cancer." | |||
"A 1998 Japanese phase I clinical trial exhibited cystostatic growth inhibition of human advanced hepatocellular carcinoma cells in vitro and showed minimum adverse effects. One showed massive coagulation necrosis of tumors after intra-arterial infusion of antineoplaston A10 I and the other showed resolution of portal vein tumor thrombosis with systemic infusion of antineoplaston A10 I." | |||
<ref> http://www.ncbi.nlm.nih.gov/m/pubmed/9769368 </ref> | |||
*Citing Secondary Source Medical Journals: Bioorganic & Medicinal Chemistry (Part II) (4/15/2009) <ref> http://www.sciencedirect.com/science/article/pii/S0968089609002478 </ref> Bioorganic & Medicinal Chemistry (Part I) (4/15/2009) <ref> http://www.sciencedirect.com/science/article/pii/S0968089609002041 </ref> Oncology reports ( 2005 ) <ref> http://www.spandidos-publications.com/or/14/2/489 </ref> Integrative Cancer Therapies (3/2004) <ref> http://ict.sagepub.com/content/3/1/47.short </ref> Il Farmaco (9/1/2001) <ref> http://www.sciencedirect.com/science/article/pii/S0014827X01011314 </ref> | |||
Thank you very much.06:32, 29 December 2012 (UTC)Didymus Judas Thomas 12/29/2012 <small><span class="autosigned">— Preceding ] comment added by ] (] • ]) </span></small><!-- Template:Unsigned --> <!--Autosigned by SineBot--> | |||
*Please add, to dispute "that antineoplaston therapy is" ... "of little promise in treating cancer." | |||
"A 1998 Japanese phase I clinical study observed rapid antitumor responses within 2-3 weeks of a combination treatment of chemoradiation therapy with antineoplastons A10 & AS2-1, and growth inhibition of cancer cells." | |||
<ref> http://www.ncbi.nlm.nih.gov/m/pubmed/9538158 </ref> | |||
*Citing Secondary Source Medical Journals: Oncology reports (8/2005) <ref> http://www.spandidos-publications.com/or/14/2/489 </ref> Oncology reports (3/2005) <ref> http://www.spandidos-publications.com/or/13/3/389 </ref> Medical Hypotheses (4/2003) <ref> http://www.sciencedirect.com/science/article/pii/S0306987703000501 </ref> | |||
Thank you very much.] (]) 07:35, 29 December 2012 (UTC)Didymus Judas Thomas 12/29/2012 | |||
*Please add, to dispute "that antineoplaston therapy is" ... "of little promise in treating cancer." | |||
"In 1997 Japanese phase I clinical trials, 2 cases of liver cancer were reviewed where Antineoplaston AS2-1 exhibited cytostatic growth inhibition of human hepatocellular carcinoma cells in vitro, showed minimum adverse effects, and may be effective and useful as a maintenance therapy. The 2 patients continued to be in good condition for more than 2 years without limitation of their normal activities." | |||
<ref> http://www.ncbi.nlm.nih.gov/m/pubmed/21590224 </ref> | |||
*Citing Secondary Source Medical Journal: Integrative Cancer Therapies (3/2004) <ref> http://ict.sagepub.com/content/3/1/47.abstract </ref> | |||
Thank you very much.] (]) 08:30, 29 December 2012 (UTC)Didymus Judas Thomas 12/29/2012 | |||
::The rational re my above posts re Japanese clinical trials/study is based on ]: he results of an early-stage clinical trial might—in some cases—be appropriate for inclusion in an article dedicated to the treatment in question or to the researchers or businesses involved in it. Such information, particularly if citing a secondary source, might also be appropriate for a well-documented section on research directions in an article about a disease." "Where in vitro and animal-model data are cited on Misplaced Pages, it should be clear to the reader that the data are pre-clinical, and the article text should avoid stating or implying that the reported findings necessarily hold true in humans." Re the 2002 entry, I have indicated the # of the references that cite Burzynski & the antineoplastons referenced. The 5 Secondary Source Journals abbreviated after that, list the # of the reference cite to the 2002 publication & the antineoplaston(s) referenced in the 5 Journal articles: 2002 - Burzynski References 8, 13, & 15 - A10 & AS2-1; Or - A10; ICT - 71 - A1, A2, A3, A4, A5, A10, A10-I, AS2-1, PB, & PN; JoCR - 1 - A10; & MH - 38 - A2, A3, A5, A10 AS2-1, AS5, & PB.23:57, 29 December 2012 (UTC)Didymus Judas Thomas 12/29/2012 <small><span class="autosigned">— Preceding ] comment added by ] (] • ]) </span></small><!-- Template:Unsigned --> <!--Autosigned by SineBot--> | |||
::Re the 1998 phase I clinical trial entry, I have indicated the antineoplastons referenced. The 5 Secondary Source Journals abbreviated after that, list the # of the reference cite to the 1998 publication & the antineoplaston(s) referenced in the 5 Journal articles: 1998 - A1, A2, A10, A10 I, & AS2-5; B&MC (II) - A1, A2, & AS2-5; B&MC (I) - A10 & AS2-5; Or - 6 - A2 & A10; ICT - 70 - A1, A2, A3, A4, A5, A10, A10-I, AS2-1, AS2-5, PG, & PN; II F - A10.] (]) 03:59, 30 December 2012 (UTC)Didymus Judas Thomas 12/29/2012 | |||
::Re the 1998 phase I clinical study entry, I have indicated the antineoplastons referenced. The 4 Secondary Source Journals abbreviated after that, list the # of the reference cite to the 1998 publication & the antineoplaston(s) referenced in the 4 Journal articles: 1998 - A10 & AS2-1; Or - A10; Or - AS2-1; & MH - 36 - A2, A3, A5, A10, AS2-1, AS5, & PB. ] (]) 05:26, 30 December 2012 (UTC)Didymus Judas Thomas 12/29/2012 | |||
::Re the 1997 Japanese phase I clinical trials entry, I have indicated the antineoplaston referenced. The Secondary Source Journal abbreviated after that, lists the # of the reference cite to the 1997 publication & the antineoplaston(s) referenced in the Journal article: 1997 - AS2-1; ICT - 69 - A1, A2, A3, A4, A5, A10, A10-I, AS2-1, AS2-5, PG, & PN. ] (]) 06:15, 30 December 2012 (UTC)Didymus Judas Thomas 12/30/2012 | |||
::*Please add, to dispute "that antineoplaston therapy is" ... "of little promise in treating cancer," re this 1996 Japanese clinical experience entry, I have indicated the # of the references that cite Burzynski & the antineoplastons referenced. The 4 Secondary Source Journals abbreviated after that, list the # of the reference cite to the 1996 publication & the antineoplaston(s) referenced in the 4 Journal articles: 1996 - The Kurume Medical Journal - Referencing Burzynski 1-4 & 6 - A10 & AS2-1; Journal of Cancer Therapy (2012) - 13 - A10, AS2-1, PB, & PN; Il Farmaco (9/1/2001) - ANP A10; Cancer Letters (8/31/2000) - 31 - A10; & Cancer Letters (7/3/2000) - A10. <ref> https://www.jstage.jst.go.jp/article/kurumemedj1954/43/2/43_2_137/_pdf </ref> "A 1996 Japanese clinical experience found antineoplaston A10 & AS2-1 had an antitumor effect in tissue culture study and an inhibitory effect on human hepatocellular carcinoma." <ref> http://www.ncbi.nlm.nih.gov/m/pubmed/8755117 </ref> <ref> http://dr-labouzeid.webs.com/A10-Cancer%20Letters%20157.pdf </ref> <ref> http://www.sciencedirect.com/science/article/pii/S0304383500004080 </ref> <ref> http://www.spandidos-publications.com/or/14/2/489 </ref> <ref> http://www.sciencedirect.com/science/article/pii/S0014827X01011314 </ref> <ref> http://www.scirp.org/journal/PaperInformation.aspx?paperID=19954 </ref> ] (]) 00:08, 31 December 2012 (UTC)Didymus Judas Thomas 12/30/2012 | |||
:::] indicates that "the results of an early-stage clinical trial..." "might—in some cases—be appropriate for inclusion in an article dedicated to the treatment in question or to the researchers ... involved in it." "Such information, particularly if citing a secondary source, might also be appropriate for a well-documented section on research directions in an article about a disease." | |||
:::Therefor, there is NO indication that "the results of an early-stage clinical trial..." are REQUIRED to cite "a secondary source." | |||
:::Therefor, per ], please create a new section titled "Disease treatment," & put any phase I clinical trial/study/experience in that new section. | |||
:::Please do not include any reference to any secondary third-party source which does not meet WP's reliable medical journal criteria. Thank you very much. ] (]) 22:09, 31 December 2012 (UTC)Didymus Judas Thomas 12/31/2012 | |||
*Per ] & ] please add at the end of the Burzynski Clinic section; based on "Complementary and Alternative Medicine in Present Day Oncology Care: Promises and Pitfalls," "Japanese Journal of Clinical Oncology" (which can be reviewed in HTML <ref> http://jjco.oxfordjournals.org/content/38/8/512.full?sid=5c546408-071e-4148-abd3-6c295dd5c6d7 </ref> or PDFs at pg. 5 of 9 & reference at pg. 9 <ref> http://jjco.oxfordjournals.org/content/38/8/512.full.pdf?sid=f8e0a3cc-2912-40e5-a7c2-dbd6db4b3c1d </ref> <ref> http://m.jjco.oxfordjournals.org/content/early/2008/08/05/jjco.hyn066.full.pdf#page=1 </ref>): | |||
:"A 2008 medical review stated that Burzynski "discovered that peptides and hormones including butyric acid and phenylbutyrate when added to cancer cells results in their differentiation, converting them into normal cells again." "In the solitary phase II study" of "Antineoplastons" , "the overall survival at 2 and 5 years was 39 and 22%, respectively, and maximum survival was more than 17 years for a patient with anaplastic astrocytoma and more than 5 years for a patient with glioblastoma. Progression-free survival at 6 months was 39%. Complete response was achieved in 11%, partial response in 11%, stable disease in 39% and progressive disease in 39% of patients." <ref> http://www.ncbi.nlm.nih.gov/m/pubmed/18682440 </ref> & | |||
*based on "The Oncologist," "Complementary and Alternative Therapies for Cancer" (which can be reviewed in HTML <ref> http://theoncologist.alphamedpress.org/content/9/1/80.full?sid=aeef6d69-bf46-4bd0-93b0-f259cd21d416 </ref> or PDFs at pg. 4 of 10 & references at pg.. 7 <ref> http://theoncologist.alphamedpress.org/content/9/1/80.full.pdf </ref> <ref> http://www.oncocure.ca/assets/byTopic/IntegrativeOncology/2-CAM%20Therapies%20in%20CA-Oncologist%202004.pdf </ref> ): | |||
:"A 2004 Memorial Sloan-Kettering Cancer Center medical review stated that antineoplastons therapy "research at the Burzynski Institute was permitted under an Investigational New Drug permit. The group’s preliminary report from a single-arm phase II study of 12 patients showed a 50% response rate." <ref> http://www.ncbi.nlm.nih.gov/m/pubmed/14755017 </ref> Thank you very much. ] (]) 23:18, 13 January 2013 (UTC)Didymus Judas Thomas 1/13/2013 | |||
*Please advise when what I requested 12/12/2012 will be done; since it is stated on the National Cancer Institute at the National Institutes of Health cancer . gov site <ref> http://www.cancer.gov/cancertopics/pdq/cam/antineoplastons/healthprofessional/page1 </ref> | |||
:In the interest of Neutrality & accuracy please change "clinical trials at the Burzynski..." to: | |||
:Nonrandomized clinical trials investigating the anticancer efficacy of antineoplastons are underway at the developer's institute.] (]) 19:39, 12 December 2012 (UTC)Didymus Judas Thomas 12/12/2012 | |||
<ref> http://en.wikipedia.org/search/?title=Burzynski_Clinic&diff=next&oldid=527745771 </ref> Thank you very much. ] (]) 02:20, 15 January 2013 (UTC)Didymus Judas Thomas 1/14/2013 | |||
*Please advise when what I requested 12/5/2012 will be done: <ref> http://en.wikipedia.org/search/?title=Talk:Burzynski_Clinic&diff=next&oldid=526643735 </ref> | |||
:Please add an Awards section: "The Academy of Comprehensive Integrative Medicine, Lifetime Achievement Award, 2012" <ref>www.acimconnect.com/Resources/Awards.aspx</ref> and/or <ref>www.acimconnect.com/Resources/Awards/StanislawBurzynskiAwardPage.aspx</ref> Thank you very much. ] (]) 03:46, 15 January 2013 (UTC)Didymus Judas Thomas 1/14/2013 | |||
== Semi-protected edit request on 5 March 2024 == | |||
::It seems clear from previous discussion on this page there is no ] to add the material you are requesting; quite the opposite in fact: a strong consensus '''not''' to add it, with plenty of reasoned argument in support. The article presents the well-sourced consensus view of the scientific/medical communities already. We shouldn't be undermining that with poorer-quality sources. ] <sup>]|]|]</sup> 03:28, 15 January 2013 (UTC) | |||
:::] "Editing from a neutral point of view (NPOV) means representing FAIRLY, PROPORTIONATELY, and as far as possible WITHOUT BIAS, ALL significant views that have been published by reliable sources. ALL Misplaced Pages articles and other encyclopedic content must be written from a neutral point of view. NPOV is a fundamental principle of Misplaced Pages and of other Wikimedia projects. This policy is NONNEGEGOTIABLE and ALL editors and articles MUST follow it." "The principles upon which this policy is based CANNOT be superseded by other policies or guidelines, or by editors' consensus." (Words CAPITALIZED for emphasis only.) | |||
:::By "e shouldn't be undermining that with poorer-quality sources," are you indicating that the "Japanese Journal of Clinical Oncology" (Oxford University Press <ref> http://en.m.wikipedia.org/Oxford_University_Press </ref>) & "The Oncologist" (AlphaMed Press <ref> http://www.wikidirectories.org/usa/north-carolina/alphamed-press-communications-media-entertainers-8191104.html </ref>) are "poorer-quality sources?" And if so, what relevance is that? | |||
:::A search of Wiki re JJCO & TO show that these 2 medical journals are cited as sources on Articles at least 500 times each. | |||
:::] "Ideal sources for biomedical material include general or systematic reviews in RELIABLE, third-party, published sources, such as REPUTABLE medical journals..." (Words CAPITALIZED for emphasis only.) | |||
:::I do not see "poorer-quality sources" listed in ]. | |||
:::If you are unwilling to comply with the above ] & ] policies, I will be happy to proceed to ] Dispute Resolution. Please advise of your intentions. Thank you very much. ] (]) 06:00, 15 January 2013 (UTC)Didymus Judas Thomas 1/14/2013 | |||
::::The article gives the consensus view of the professional community, as represented by the ] and ]. In relation, other one-off articles are "poorer-sources", and we must not use them to undermine the clearly presented consensus. ] <sup>]|]|]</sup> 10:58, 15 January 2013 (UTC) | |||
:::::I understand that it is your intent to ignore ] & "ALL significant views..." & to ignore ] "deal sources for biomedical material include general or systematic reviews in RELIABLE, third-party, published sources, such as REPUTABLE medical journals..." & instead rely on your "poorer-sources" & "consensus" statement which does not override ] "he principles upon which this policy is based CANNOT be superseded by OTHER POLICIES or GUIDELINES..." (Words CAPITALIZED for emphasis only.) Therefore, I will proceed with ]. Thank you very much. ] (]) 07:56, 16 January 2013 (UTC)Didymus Judas Thomas 1/16/2013 | |||
{{edit semi-protected|Burzynski Clinic|answered=yes}} | |||
<!-- Sub section to keep things tidy --> | |||
The article is slanderous. Reliable source : Burzynski documentary. Cancer cure cover up. It’s big business. He’s not a quack. Big $ has all the power to run smeer campaigns on anyone they like. The fda & Texas medical board were so despicable & unashamedly bold in taking him down because of his non invasive EFFECTIVE treatment of cancer. There are so many testimonials court appearances protests & news reports in this 2 part documentary it’s mind blowing. ] (]) 05:57, 5 March 2024 (UTC)<Eric Merola> | |||
===Use of primary sources (moved from the section above)=== | |||
:{{not done}} That documentary is not a reliable source. Far from it. ] (]) 06:01, 5 March 2024 (UTC) | |||
Hey, all this is getting slightly off-topic, to be very diplomatic. The bottom line is, ''there are no published secondary sources on antineoplastons conformant to ], so we can only use primary sources '''with utmost care and without jumping to conclusions'''''. In particular, it's okay to mention that certain trials were reported ''by the researchers conducting these trials'' as having such and such efficacy, adding that one or two third-party studies were not able to establish the efficacy. Definitely, it's not okay to paraphrase any of the study conclusions (that including the one by Mayo Clinic). Also, any sources like "Quackwatch", etc., are not covered by "reliable secondary sources" as understood by ]. To stress again: antineoplastons have ''not'' been confirmed effective (we have no independent confirmation) but have not been confirmed ineffective, either (again, for lack of third-party studies), while the actual problem with the Burzynski Clinic (not with chemical compounds!) has been their ethically doubtful marketing of these chemical compounds as "cancer therapy". Please may someone edit the article in this spirit, I am sort of fed up with all this beating a dead horse... <span style="font-family: 'Candara', sans-serif; font-weight: bold; text-shadow: #AAAAFF 0.2em 0.2em 0.1em; class: texhtml">]</span> 23:15, 28 December 2012 (UTC) | |||
: ] has "reliable primary sources may occasionally be used with care as '''an adjunct to the secondary literature'''" (my emphasis). Doesn't that put an end to the matter? (And isn't Quackwatch established RS on questions of quackery?) ] (]) 23:19, 28 December 2012 (UTC) | |||
:: ] advises further: "edits that rely on primary sources should only describe the conclusions of the source, and should describe these findings clearly". Which is more than clear that edits based on primary sources alone are admissible. Did you skip this sentence on purpose? It is common sense that where secondary sources are not yet available (as is the case with many recent discoveries), editors may resort to relying on primary sources. That's the end of the matter, isn't it? If still not convinced, I suggest to ask at ]. <span style="font-family: 'Candara', sans-serif; font-weight: bold; text-shadow: #AAAAFF 0.2em 0.2em 0.1em; class: texhtml">]</span> 23:52, 28 December 2012 (UTC) | |||
== Semi-protected edit request on 11 October 2024 == | |||
:::You're citing that as if it overrode the requirement that Alexbrn mentioned, but to me it reads as if it is meant to further limit the use of primary sources. MEDRS also advises to use secondary sources to determine due weight, so no, it's not like we are allowed to use primary sources whenever secondary sources are not yet available. Did you check the sources Didymus Judas Thomas is unloading here? Most are on cell lines or case reports, and some don't even deal with Burzynski's treatment. I don't think that's the sort of primary sources that's admissible, but just to be sure I'll add a request at ]. --] (]) 08:17, 29 December 2012 (UTC) | |||
::::No primary sources should be used. We have secondary sources as per "The consensus among the professional community, as represented by the American Cancer Society and Cancer Research UK among others, is that antineoplaston therapy is unproven" We should not be using primary source to refute secondary ones. WP:MEDRS is very clear about this. ] (] · ] · ]) (if I write on your page reply on mine) 08:41, 29 December 2012 (UTC) | |||
::::: Neither ACS nor CR offer sources compliant with ]. We are talking about ''review articles'' published in peer-reviewed journals, not about opinions placed on websites of societies and associations. Personally, I would even rephrase this unfortunate "consensus among the professional community" as there is hardly any consensus in medicine as regards cancer treatment. We have here primary sources (with all the deficiencies of them being primary) ''vs.'' other primary sources and a bunch of sources non-MEDRS compliant. It's a difficult task to balance the section on "antineoplastons" in lack of secondary sources on their efficacy. Just we have to come to terms with this fact: '''there are no secondary sources as regards efficacy of antineoplastons'''. None. Period. (The reason perhaps being too few independent studies of these compounds to warrant a review). | |||
::::: Hence, I suggest: | |||
:::::* to stop using the word "therapy" with "antineoplastons": this use should not be called a therapy unless it is formally approved and recognised as such. | |||
:::::* to stop making any claims in this article as regards efficacy (either way) of these compounds: there is no reliable proof to confirm or deny it. We only can - and should - mention the diverse views in both Burzynski's (and Japanese) primary sources and the views of those who claim to represent the "scientific community" (also, as regards lack of plausible, scientific explanation of the mechanism of action as well as lack of independent studies). | |||
::::: As regards the question whether primary sources alone can be used - yes they can, ] nowhere prohibits their use. There has been a couple of discussions on the matter (see e.g. here: ], the discussion makes a few interesting remarks). Still, this should be discussed and clarified on the policy level, not here. <span style="font-family: 'Candara', sans-serif; font-weight: bold; text-shadow: #AAAAFF 0.2em 0.2em 0.1em; class: texhtml">]</span> 09:41, 29 December 2012 (UTC) | |||
{{edit semi-protected|Burzynski Clinic|answered=yes}} | |||
::::::MEDRS allows the use of statements from "medical and scientific organisations"; you're also wrong to claim no (independend) review deals with this treatment. There's an older one that only focusses on this "therapy" - , and a newer one that discusses the treatment amongst others - . We're using the latter in the article. MEDRS clearly states that we cannot use primary studies to contradict reliable secondary sources, so yes, primary sources can sometimes be used but no, they can not in the way you seem to imply. --] (]) 10:34, 29 December 2012 (UTC) | |||
Under "Antineoplaston Therapy": | |||
:::::::Six words/Doc James, I am not sure what relevance these alleged "reliable secondary sources" and "consensus among the professional community" have re ] considering my previous post re the American Cancer Society & Cancer Research UK, & the 4/2004 JAMA article which relies on; as I posted above, a "failed study" that was "stopped before it was possible to determine the effectiveness of antineoplastons." Since 4/2004, at least 16 ANP articles; 15 in PubMed, have been published in the U.S., Japan, & China (2004-2009) & since the "failed" NIH studies ended 12/1995, 33 ANP related articles; 28 in PubMed, have been published in the U.S., Japan, Egypt, Poland, Korea, & Great Britain (12/1995.-4/2004); which have included phase I & II clinical trial publications. When ANP research has been done in at least 6 countries, I feel it is presumptuous to claim a "consensus among the professional community" based upon 2 countries out of 6, & claim "reliable secondary sources" based on where a "study failed to be completed."] (]) 18:15, 29 December 2012 (UTC)Didymus Judas Thomas 12/29/2012 | |||
::::::::Agree with Six words/Doc James, we have multiple secondary sources noting antineoplaston don't work. Should good secondary sources state otherwise, we can add them, but to use our own personal opinion (i.e. ]) to try to overturn multiple high quality sources is folly, no matter how many poor quality primary sources are produced. ] (]) 19:32, 29 December 2012 (UTC) | |||
{{outdent}} Exactly that. The consensus of reliable independent secondary sources is that ANPs are of little promise, and that Burzynski has not published useful data. Pointing to the (actually very small for 30 years of such apparently assiduous work) primary sources of Phase I studies does not in any way change the fact that 60 Phase II trials have been registered, millions charged for participation in them, and not a single one has been published. The world, right now, considers Burzynski to be at best unethical and at worst a quack, and Misplaced Pages is not the place to fix that because we are here to reflect reality not to influence it. This discussion is circular and should probably stop now. <b>]</b> <small>(])</small> 08:58, 30 December 2012 (UTC) | |||
:Yobol & Guy, thank you for getting on your Soap Box ]. | |||
:Are you indicating that: | |||
:<ref> http://en.m.wikipedia.org/Kurume_University </ref> Department of Surgery, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka, Japan | |||
:Department of Anesthesiology, Kurume University, School of Medicine, Fukuoka-ken, Japan. | |||
:Department of Radiology, Kumabe Hospital, Kurume University School of Medicine, Kurumeshi, Fukuokaken, Japan. | |||
:Kurume University, School of Medicine: Department of Surgery, Department of Internal Medicine, Department of Radiology, Kurume, Fukuoka, Japan | |||
:<ref> http://en.m.wikipedia.org/Shandong_University </ref> School of Pharmaceutical Sciences, Shandong University, No.44 WenhuaXi Road, Ji'nan, Shandong Province, PR China, & | |||
:<ref> http://en.m.wikipedia.org/Mansoura_University </ref> Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt | |||
:are NOT "reliable secondary sources" but are "poor quality primary sources" &/or "low quality primary sources?" | |||
:Because they are Universities which have done antineoplaston research &/or phase I & II clinical trials based on Burzynski's research, & I want to contact them & let them know that they are "poor quality primary sources" &/or "low quality primary sources" & request that WP post that on their WP articles if that is what you mean. | |||
:Guy, I can understand why you would suggest "his discussion is circular and should probably stop now," since you got your 2 cents in. | |||
:On cancer . gov, the National Cancer Institute, at the National Institutes of Health, has indicated on the "Antineoplastons: Human/Clinical Trials" page: "PUBLICATIONS have taken the form of case reports, phase I clinical trials, toxicity studies, and PHASE II CLINICAL TRIALS." | |||
:Additionally, it then states: "Table 2 summarizes the following clinical trials and appears at the end of this section." | |||
:It then cites, at the bottom of the page," References" for Burzynski's Phase I & II Clinical Trial publications." <ref> http://www.cancer.gov/cancertopics/pdq/cam/antineoplastons/healthprofessional/page5 </ref> | |||
:Are y'all indicating the National Cancer Institute at the National Institutes of Health is a "poor quality primary source" &/or "low quality primary source?" <ref> http://en.m.wikipedia.org/National_Cancer_Institute </ref> | |||
:I want to request that WP post that on their WP articles if that is what you mean. | |||
:"ot a single one has been published. The world, right now, considers Burzynski to be at best unethical and at worst a quack ..."? ] -- such baseless conspiracy theory nonsense merits no consideration. | |||
:I am here to reflect reality. Thank you very much. ] (]) 04:04, 31 December 2012 (UTC)Didymus Judas Thomas 12/30/2012 | |||
Since 2011, the clinic has marketed itself as offering "personalized gene-targeted cancer therapy", which has stirred further controversy. David Gorski argues that the concept of "personalised cancer therapy" is "more of a marketing term than a scientifically meaningful description". According to Gorski, a research oncologist, it appears unlikely that the Burzynski clinic would indeed be able to actually personalise gene-targeting therapies, i.e., "identify who would benefit from specific targeted therapies simply from blood tests," as Burzynski claims, since there are no proven methods to achieve this. Consequently, many reject Burzynski's claim of offering personalized medicine, because in reality his patients are administered untested combinations of various approved and unapproved medications, without a sound rationale for a given combination and without "any concern for potential adverse reactions". | |||
::If we were in the 1980s you might actually have a point, it was a "new treatment" back then. This, however, is the year 2013, and the independent secondary literature is clear. Primary sources, even if they were excellent, wouldn't outweigh secondary sources - it's as simple as that - and that's what everyone here is saying, so don't put words in people's mouths. --] (]) 10:13, 1 January 2013 (UTC) | |||
:::So you have a problem with me changing their meaning but not them changing mine. So much for ], but then again, Burzynski's work is still being referenced: 5/2011 BMC Chemical Biology, as References 4 & 31 <ref> http://www.springerlink.com/content/a33r46q2l63x7375 </ref> | |||
:::& the research I am referencing has been published up to & including 10/2010 Journal of Radioanalytical and Nuclear Chemistry <ref> http://www.springerlink.com/content/tj0177485773007t </ref> ] (]) 08:08, 2 January 2013 (UTC)Didymus Judas Thomas 1/2/2012 | |||
I suggest removing this paragraph or reworking it entirely. Testing for genetic mutations is the premise of finding the appropriate therapy for many types of cancer. While Dr. Gorski may have a point regarding the semantics, and while his point is somewhat related to the Burzynski Clinic's claims of providing "personalized" services, a reader might draw the conclusion that genetic testing for cancer treatment does not exist. ] (]) 19:05, 11 October 2024 (UTC) | |||
::::When will you understand that it's not enough that Burzynski's research "is referenced"? You need to cite articles that discuss this treatment in detail. Secondary sources. | |||
::::BMC Chemical Biology: (Research article) ''Chemical modification of L-glutamine to alpha-amino glutarimide on autoclaving facilitates Agrobacterium infection of host and non-host plants: A new use of a known compound''. | |||
::::Journal of Radioanalytical and Nuclear Chemistry: ''(S)-2-((S)-2-(4-(3- fluoropropyl)benzamido)-3-phenylpropanamido)pentanedioic acid labeled with 18F'' | |||
::::Neither discusses the treatment in detail and neither could be used to refute the secondary sources our article is citing. --] (]) 09:00, 2 January 2013 (UTC) | |||
:::::When will you understand that the USA is not the only country in the world & that research has been done in Poland, Korea, Egypt, Japan, & China referred to Burzynski's work 6/8/2012 in conjunction with the Department of Molecular Genetics and Microbiology, Shands Cancer Center, University of Florida, Gainesville, FL, USA. So you can pretend you're back in the 80's all you want while independent researchers in other countries verify Burzynski's research; including Phase III Clinical Trials in breast cancer, NSCLC, & primary hematoma reported 6/2005 by China/Taiwan in the Chinese Journal of Clinical Oncology. ] (]) 22:57, 8 January 2013 (UTC)Didymus Judas Thomas 1/8/2013 | |||
] '''Not done for now''': please establish a ] for this alteration ''']''' using the {{Tlx|Edit semi-protected}} template.<!-- Template:ESp --> ] (]) 20:22, 18 October 2024 (UTC) | |||
== References == | |||
{{hat|List of footnotes}} | |||
<references /> | |||
{{hab}} | |||
== |
== Help I just want to add another film name == | ||
I tried to edit this page to add in another film that was directed by Eric Merola with a release date of 2016. The name of the film is (Burzynski: Cancer Cure Cover Up). For some reason I ended up being posted in the M.R. Hammer talk. | |||
Or is this Talk page becoming difficult to use because of one ]'s additions to it? I left a message on the editor's Talk page a while ago asking for better formatted contributions ... but to no avail. ] (]) 08:20, 29 December 2012 (UTC) | |||
I know the subject matter is controversial, however the film I mentioned is clearly mentioned on the IMDb website and I just watched it on the Tubi streaming service. This film clearly exists. Thanks for any help in this matter ] (]) 02:15, 31 December 2024 (UTC) | |||
::Agreed -- chaotic and counterproductive. The intent of the SPAs main argument is to counter the prevailing POV of reliable secondary sources with a slew of low quality primary sources -- clearly prohibited by ]. The other argument is that the secondary sources (i.e., respected cancer organizations, FDA, etc.) are not reliable because they are Burzynski's "competitors" -- such baseless conspiracy theory nonsense merits no consideration whatsoever. ] (]) 22:18, 29 December 2012 (UTC) | |||
* Topic ban time per ]. This is a waste of effort: the SPA is a True Believer and is using the usual filter that such people employ in order to view all sources as saying something the reliable secondary sources indicate they don't. <b>]</b> <small>(])</small> 08:47, 30 December 2012 (UTC) | |||
::Yobol, Rhode Island Red, & JzGIGuy, thank you for getting on your Soap Box ], & RIR, thank you for misrepresenting the "facts" about what I posted 12/28/12. | |||
::I think the much bigger problem is individuals on WP who ignore "facts" & misrepresent what people post. | |||
::Yobol & RIR, are you indicating that | |||
::<ref> http://en.m.wikipedia.org/Kurume_University </ref> Department of Surgery, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka, Japan | |||
::Department of Anesthesiology, Kurume University, School of Medicine, Fukuoka-ken, Japan. | |||
::Department of Radiology, Kumabe Hospital, Kurume University School of Medicine, Kurumeshi, Fukuokaken, Japan. | |||
::Kurume University, School of Medicine: Department of Surgery, Department of Internal Medicine, Department of Radiology, Kurume, Fukuoka, Japan | |||
::<ref> http://en.m.wikipedia.org/Shandong_University </ref> School of Pharmaceutical Sciences, Shandong University, No.44 WenhuaXi Road, Ji'nan, Shandong Province, PR China, & | |||
::<ref> http://en.m.wikipedia.org/Mansoura_University </ref> Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt | |||
::are NOT "reliable secondary sources" but are "poor quality primary sources" &/or "low quality primary sources?" | |||
::Because they are Universities which have done antineoplaston research &/or phase I & II clinical trials based on Burzynski's research, & I want to contact them & let them know that they are "poor quality primary sources" &/or "low quality primary sources" & request that WP post that on their WP articles if that is what you mean. | |||
::RIR, re your "he other argument is that the secondary sources (i.e., respected cancer organizations, FDA, etc.) are not reliable because they are Burzynski's "competitors" post, that is NOT all I posted. | |||
::I posted that the: "(1) American Cancer Society &(2) Cancer Research UK ..." have "nothing re Antineoplastons on PubMed ..." & "(3) Memorial Sloan-Kettering has 1 PubMed article re Antineoplastons ..." | |||
::I did NOT post that the FDA was a competitor of Burzynski. | |||
::JzG, I can understand why you would suggest "opic ban time ..." since you got your 2 cents in. | |||
::On cancer . gov, the National Cancer Institute, at the National Institutes of Health, has indicated on the "Antineoplastons: Human/Clinical Trials" page: "PUBLICATIONS have taken the form of case reports, phase I clinical trials, toxicity studies, and PHASE II CLINICAL TRIALS." | |||
::Additionally, it then states: "Table 2 summarizes the following clinical trials and appears at the end of this section." | |||
::It then cites, at the bottom of the page," References" for Burzynski's Phase I & II Clinical Trial publications." <ref> http://www.cancer.gov/cancertopics/pdq/cam/antineoplastons/healthprofessional/page5 </ref> | |||
::Are y'all indicating the National Cancer Institute at the National Institutes of Health is a "poor quality primary source" &/or "low quality primary source?" <ref> http://en.m.wikipedia.org/National_Cancer_Institute </ref> | |||
::I want to request that WP post that on their WP articles if that is what you mean -- such baseless conspiracy theory nonsense merits no consideration. Thank you very much. ] (]) 03:33, 31 December 2012 (UTC)Didymus Judas Thomas 12/30/2012 | |||
::: One of us is a single-purpose advocacy account for a doctor with a poor reputation, the other is a long-term member of the Misplaced Pages community, an admin with tens of thousands of edits to thousands of articles. Guess which is which, and why that might be significant? <b>]</b> <small>(])</small> 19:48, 4 January 2013 (UTC) | |||
::::One of us is biased & promotes their bias as an editor on WP & could care less about ] because of their bias & has no explanation as to how a doctor with an alleged "poor reputation" continues to be referenced 6/8/2012 in work done in China & the USA by independent scientific researchers as noted in Biochemical and Biophysical Research Communications ] (]) 23:07, 8 January 2013 (UTC)Didymus Judas Thomas 1/8/2013 |
Latest revision as of 10:49, 31 December 2024
This is the talk page for discussing improvements to the Burzynski Clinic article. This is not a forum for general discussion of the article's subject. |
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
Archives: Index, 1, 2, 3, 4, 5, 6, 7, 8Auto-archiving period: 3 months |
The subject of this article is controversial and content may be in dispute. When updating the article, be bold, but not reckless. Feel free to try to improve the article, but don't take it personally if your changes are reversed; instead, come here to the talk page to discuss them. Content must be written from a neutral point of view. Include citations when adding content and consider tagging or removing unsourced information. |
This page is not a forum for general discussion about Burzynski Clinic. Any such comments may be removed or refactored. Please limit discussion to improvement of this article. You may wish to ask factual questions about Burzynski Clinic at the Reference desk. |
This article must adhere to the biographies of living persons (BLP) policy, even if it is not a biography, because it contains material about living persons. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately from the article and its talk page, especially if potentially libellous. If such material is repeatedly inserted, or if you have other concerns, please report the issue to this noticeboard.If you are a subject of this article, or acting on behalf of one, and you need help, please see this help page. |
This article is rated B-class on Misplaced Pages's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||||||||||||||||||
|
This article has been mentioned by a media organization:
|
Text and/or other creative content from this version of Burzynski Clinic was copied or moved into Stanislaw Burzynski with this edit on 12:03, 29 August 2012. The former page's history now serves to provide attribution for that content in the latter page, and it must not be deleted as long as the latter page exists. |
The contentious topics procedure applies to this page. This page is related to pseudoscience and fringe science, which has been designated as a contentious topic. Editors who repeatedly or seriously fail to adhere to the purpose of Misplaced Pages, any expected standards of behaviour, or any normal editorial process may be blocked or restricted by an administrator. Editors are advised to familiarise themselves with the contentious topics procedures before editing this page. |
Arbitration Ruling on the Treatment of Pseudoscience
In December of 2006 the Arbitration Committee ruled on guidelines for the presentation of topics as pseudoscience in Misplaced Pages:Requests for arbitration/Pseudoscience. The final decision was as follows:
|
Good Evidence for Antineoplaston Efficacy from Japan
A 2015 study from Ogata et al. titled "Randomized Phase II Study of 5-Fluorouracil Hepatic Arterial Infusion with or without Antineoplastons as an Adjuvant Therapy after Hepatectomy for Liver Metastases from Colorectal Cancer" (https://doi.org/10.1371/journal.pone.0120064) records that in an open label, non-blinded but randomized phase II study cancer specific survival rate (CSS) was significantly higher in the antineoplaston arm vs. the control (i.e. non-antineoplaston) arm. This study had 65 patients enrolled, with 33 of those in the control group not receiving antineoplaston therapy, and 32 receiving the treatment. Median survival in the antineoplaston group, was, in fact, 67 months vs. 39 months, with a CSS of 60% and 32%, respectively. Furthermore, there were no incidental serious toxicities or apparent liver or kidney damage. Now, I demand an answer on moral grounds: Why is this study not mentioned in this article? I hold a biochemistry degree and a master's degree in medical science and would like to know why this isn't mentioned in the article.
Additionally, Ushijima et al. in the journal Oncology Reports published an article called "Demethylation effect of the antineoplaston AS2-1 on genes in colon cancer cells" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868501/) which clearly reports epigenetic changes in colon cancer cells, changes which are very likely to suppress cancer development and progression using the body's natural tumor suppression system. This work from these researchers is highly suggestive, just as Dr. Burzynski has stated in on-the-record interviews, that epigenetic modulations in response to the presence of antineoplastons are, in whole or in part, how they fight cancer.
While this is not absolute proof of antineoplaston therapy's efficacy, it is extremely favorable evidence and analysis, and I would just like to know how anybody could look at these studies and act as if the whole antineoplaston therapy question should just be dismissed as quackery.
Misplaced Pages - in fact, anybody - I ask you: why is none of this mentioned in the article on the topic? In fact, why are the staff at Misplaced Pages not seriously disturbed at the lack of research into this topic? How could anybody look at these studies and not demand further investigation? 2600:1700:407B:2810:153:D9CA:A5FC:2ECC (talk) 03:09, 22 January 2023 (UTC)
- Read WP:MEDRS and WP:PRIMARY. We wait until there are favorable secondary sources that collect primary ones. That is also how competent scientists judge those things. Accepting primary studies at face value is naive and amateurish. --Hob Gadling (talk) 06:49, 22 January 2023 (UTC)
- I appreciate your reply.
- 1. Who said anybody should "just accept" this or that study "at face value"? - nobody, that's who. The point I made is that this is an example of a professional, independent, peer-reviewed clinical trial which produced results that unambiguously suggest that antineoplastons have clinical efficacy. Yes - duh, obviously - it could be a fluke - it's just that, without evidence to the contrary it is unlikely to be a fluke. Does such evidence exist, or not? No clinician in their right mind would say that "this single study means we need to start giving patients antineoplastons right away!" ...but no objective clinician could possibly look at that study and honestly say that this doesn't warrant interest. Given the history of the field any physician or researcher would be PERFECTLY within their rights to look at that study and say "meh, I'll bet it's a fluke - happens all the time," but that sort of reply is not science. Only follow-up studies that demonstrate no replication of effect WOULD be evidence. A study like that warrants follow up, and that's a plain fact. To ignore it wholesale in an article which is designed precisely to deal with the very controversy of the efficacy of the drugs is NOT objective or neutral.
- 2. Misplaced Pages's own policy (the one you linked me to) on Primary Sources (from "Reliable sources") states:
- =======
- "A primary source may be used on Misplaced Pages only to make straightforward, descriptive statements of facts that can be verified by any educated person with access to the primary source but without further, specialized knowledge. For example, an article about a musician may cite discographies and track listings published by the record label, and an article about a novel may cite passages to describe the plot, but any interpretation needs a secondary source."
- =======
- And here :
- =======
- Primary sources should NOT normally be used as a basis for biomedical content. This is because primary biomedical literature is exploratory and often not reliable (any given primary source may be contradicted by another). Any text that relies on primary sources should usually have minimal weight, only describe conclusions made by the source, and describe these findings so clearly that any editor can check the sourcing without the need for specialist knowledge. Primary sources should never be cited in support of a conclusion that is not clearly made by the authors
- =======
- Mentioning the results of the aforementioned 2015 Ogata et al. study clearly would not violate the explicit, stated policy, and in fact would do wonders for the objectivity of the article.
- 3. This article currently says verbatim that "there is no clinical evidence of the efficacy of these methods." The authors throughout the Wiki article were very careful to be objective and only report the opinions of institutes and bodies that stated that antineoplastons were not effective, instead of making categorical statements of fact or categorically characterizing the entire extent field of evidence as one way or the other. That is objectivity. However, in the aforementioned statement, this standard was dropped and the article makes a categorical statement which is, in fact, false, because the 2015 Ogata et al. study is an exact contradiction to the statement.
- 4. I have no serious academic interest, economic incentive or personal conflict on this matter at all. I just care about objectivity and have an interest in healthcare. Surely you're a clinician or scientist of some kind (I would hope) - what exactly IS your view on the 2015 Ogata et al. study? Do you think it was a fluke?
- I apologize for the length of my reply. 2600:1700:407B:2810:6015:D9D0:4A7D:D0AE (talk) 16:05, 22 January 2023 (UTC)
- I have an idea of Hobs opinion, but instead I'm going to give you mine. For us encyclopedia editors, Ogata et al is entirely unimportant, because of WP:RS and WP:MEDRS. - Roxy the dog 16:21, 22 January 2023 (UTC)
- Uncannily accurate. --Hob Gadling (talk) 17:11, 22 January 2023 (UTC)
- Agree. Guy (help! - typo?) 22:13, 24 January 2023 (UTC)
- Let me explain. When summarising the 2015 Japanese study, you quoted raw survival data. This means that you've disregarded the existence of confounders and, essentially, the entire statistical model. However, the study conclusion reads: "Overall survival was not statistically improved (p=0.105) in the AN arm (n=32). RFS was not significant (p=0.343)." As you may know, the p-value indicates, in lay terms, to what extent the observed outcome can be credited to the studied intervention. Commonly, statistical models require p not to exceed 0.05 for the results to be considered statistically significant.
- Here in this study, p was significantly higher, which essentially means that the observed outcome (e.g., difference in survival) has not been solely due to the intervention (antineoplaston therapy), since other factors have influenced it more strongly.
- To but it bluntly, the study offers some evidence that antineoplastons are not effective in the studied dose for this type of cancer (although, being an open-label study, its evidence value is anyway low).
- If you insist on including the paper, I'm ok with summarising it along the lines: In a 2015 randomised open-label study carried out in Japan, 5-fluorouracil was ineffective as an adjuvant therapy for liver metastasis resulting from colorectal cancer. — kashmīrī 17:09, 22 January 2023 (UTC)
- Your analysis is excellent, and we should definitely not include it for those reasons. Guy (help! - typo?) 22:15, 24 January 2023 (UTC)
- JzG, did you read the article before proclaiming Kashmirir's analysis excellent? RudolfoMD (talk) 04:31, 17 January 2024 (UTC)
- Yes. My personal view: Primary sources with "antineoplastons" as an adjuvant therapy for liver cancer were, and remain, irrelevant to the inflated and entirely unsupportable claims by Burzynski for use of his quackery as a magical primary therapy (in the words of his stans, a cure) for incurable brain cancers, based on nearly half a century of utterly underwhelming results and large numbers of (well documented) dead patients bilked out of vast sums of money.
- My Misplaced Pages policy view: Misplaced Pages is not here to blaze the trail in promoting commercial claims where the consensus in the relavant professional community is that tsaid claims are at best nonsense, and at worst entirely fraudulent.
- When all the reliable secondary sources show he's a mendacious quack, so do we. Guy (help! - typo?) 19:24, 17 January 2024 (UTC)
- It was a simple yes/no question - the 2015 Japanese study - did you read it before proclaiming Kashmirir's analysis excellent or not. Yes, you say. I believe you know what a primary endpoint is, and you know that the study that you read met its primary endpoint. And yet you insist an analysis is excellent that misrepresented that primary endpoint (p=0.037 for CSS) as not statistically significant. That is not excellent analysis. It seems to me your preconceptions are clouding your judgement. That's the most charitable interpretation of the facts in front of me I can come up with. How do you explain it? I expected the science and data to show Burzynski's work to be without much merit. But what I'm finding so far is multiple extremely flawed criticisms based on falsehoods. One of which has already been acknowledged and fixed. RudolfoMD (talk) 02:10, 18 January 2024 (UTC)
- JzG, did you read the article before proclaiming Kashmirir's analysis excellent? RudolfoMD (talk) 04:31, 17 January 2024 (UTC)
- 1. I'm sorry but did you not read the rest of the findings section you quoted from??! It's not even five or six sentences long! And the very next sentence directly after the one you quoted states:
- Nevertheless, the CSS rate was significantly higher in the AN arm versus the control arm (n=33) with a median survival time 67 months (95%CI 43-not calculated) versus 39 months (95%CI 28-47) (p=0.037) and 5 year CSS rate 60% versus 32% respectively.
- At the risk of being redundant, I will point out that the P-value is below the threshold of 0.05 you selected! Not that p = 0.05 is some "special" threshold - it's just a convention. Many researchers value a p of 0.1, some 0.05, some 0.01 - those are all not uncommon p values. Either way it doesn't matter since you chose the p of 0.05, which you must not have realized the study conclusion did in fact satisfy. Did you not read the paltry few sentences of the article summary? Or are you seriously purposefully distorting the information? (See #3 below)
- 2. The Misplaced Pages policy states: "Any text that relies on primary sources should...only describe conclusions made by the source ... Primary sources should never be cited in support of a conclusion that is not clearly made by the authors
- Now, your suggested "summary" is a complete reversal of the conclusion the study authors reach, which is described in the single sentence - not difficult to read or see - in the "Interpretations" paragraph of the study: Antineoplastons (A10 Injection and AS2-1) might be useful as adjunctive therapy in addition to HAI after hepatectomy in colorectal metastases to the liver. To include YOUR summary of the article would be a direct violation of the Misplaced Pages guideline you originally invoked!
- 3. Perhaps most telling of all, you either didn't read the paltry few sentences of the article summary, or had more insidious designs. I'm really just quite perplexed.
- (A) Your "explanation" - which this person "Guy" bizarrely praised as "excellent" - suggested that a summary of the article could be included as In a 2015 randomised open-label study carried out in Japan, 5-fluorouracil was ineffective as an adjuvant therapy for liver metastasis resulting from colorectal cancer.
- Excuse me, but what...the hell? The study was not testing 5-fluorouracil! It was not the adjuvant! You obviously didn't understand the simple trial! The article was testing addition of antineoplastons TO a therapeutic HAI (Hepatic Arterial Infusion) of 5-fluorouracil - the 5-fluorouracil is not an antineoplaston and is a known chemotherapeutic for this adminstration route - which is WHY they were using it in the first place! The antineoplastons were being added as adjuvants to be tested - BOTH groups got 5-fluoruracil, ONE got the antineoplastons.
- (B) You obviously didn't understand the study despite it being incredibly simple. You didn't understand what was being tested, didn't know that 5-fluorouracil was not an antineoplaston, didn't know that 5-fluorouracil via HAI was a known chemotherapeutic, and thought that the data suggested 5-fluorouracil was ineffective, when in fact it is KNOWN to be effective, and the data in fact suggested that the antineoplaston WAS effective. I mean, this is just a ridiculous misinterpretation (or something) on your part - I'm sorry.
- 4. While your characterization of a study on basic research as "utterly useless" regarding clinical applications is an absurd exaggeration, it's perfectly legitimate to suggest it doesn't belong in a subsection, perhaps, about clinical results of a trial of the drug. But to call such basic research "utterly useless" is mind-numbingly obtuse - you can't GET to clinical trials without some plausible mechanism or evidence buttressed by basic research. I have no problem not mentioning the known epigenetic activity of antineoplastons in a summary of clinical trials - but to say it just shouldn't be included anywhere in an article about Burzynski and his therapy on antineoplastons is asinine. It's a known effect of the drug in cancerous cell lines and you have huge portions of an article dedicated to - supposedly - objectively analyzing the efficacy, plausibility and suitability of Burzynski's therapy for cancer treatments! To dismiss it as "utterly useless" is absurd!
- 5. I apologize for any overtly rude-sounding aggression but I was just left gobsmacked and dumbfounded by your response. I thought the people who would be editing a Misplaced Pages article about a supposed quack cancer treatment would be highly qualified experts in a closely related field, if not in the field itself. Instead it seems as if you weren't even familiar with a common chemotherapeutic agent, didn't know what kind of medication it was, and were unable to understand a simple article.
- 6. Let me be clear: I have no intention to continuously revisit these posts over and over again, though perhaps I might if I must. I feel I have said enough that needs to be said and the record will show it here. As I said before I have NO serious dog in this fight or conflict of interest, and I even am SUSPICIOUS of Burzynski's therapy myself! 40+ years of antineoplaston existence - you would think - WOULD render something more substantial by now if the therapy is legitimate. In addition, I'm fully aware that Burzynski has registered numerous trials - even many dozens which he suspiciously hasn't published the results of - and in the long run you're bound to get flukes. This study could have been a fluke - BUT THE EVIDENCE does NOT suggest that! To fail to mention this study in the kind of article you've written is simply NOT objective analysis and below the kind of objectivity I would expect from Misplaced Pages, which I have donated to more than once in the past and find an invaluable source of information. The fact is sharing these kinds of controlled trial results CANNOT damage humanity - it will all be part of a record that people are entitled to know about, and to FAIL to mention it is just as bad as promoting false information.
- Again I'm sorry if this sounded rude but direct confrontation of distortion and confusion can often sound rude when its sole purpose is to get closer to accurate representation of the truth. I really hope you consider this further regardless of whatever decision you make and appreciate your time. I'm sorry again for the length of my writing here but I know of no other way to be thorough and as I said before I hope I do not find myself coming back to this repeatedly since I believe the analysis is self-evident and virtually all that I needed to say has been said here, though it be lengthy. 2600:1700:407B:2810:D80F:D35D:F99E:FBCA (talk) 04:45, 27 January 2023 (UTC)
- See the second sentence of this reply to you. - Roxy the dog 05:48, 27 January 2023 (UTC)
Check these recent edits of mine. Burzynski has published a lot more results than the article lets on. Bon courage insisted on stonewalling when I tried to work with them to correct the false/outdated claim in the article that "that researchers other than Burzynski and his associates have not been successful in duplicating his results". (Though just before finishing this comment, I saw some further edits have been made - hope they are a pleasant surprise.) RudolfoMD (talk) 04:42, 17 January 2024 (UTC)many dozens which he suspiciously hasn't published the results of
— User:2600:1700:407B:2810:D80F:D35D:F99E:FBCA 04:45, 27 January 2023 (UTC)
- Your analysis is excellent, and we should definitely not include it for those reasons. Guy (help! - typo?) 22:15, 24 January 2023 (UTC)
- Re. the Ogata study, it's all basic research – utterly useless for an article about clinical applications. We don't even need to go into the primary vs secondary debate. — kashmīrī 17:17, 22 January 2023 (UTC)
- You grossly misrepresented the findings, ignoring the primary endpoint.
That's a deceptive summary. You misrepresented the primary endpoint (p=0.037 for CSS) as not statistically significant when it was. You don't want to walk it back, fine. But I'm getting a lot of pushback when I'm removing demonstrably false, defamatory information violating BLP that I stumbled upon. RudolfoMD (talk) 04:21, 18 January 2024 (UTC)If you insist on including the paper, I'm ok with summarising it along the lines: In a 2015 randomised open-label study carried out in Japan, 5-fluorouracil was ineffective as an adjuvant therapy for liver metastasis resulting from colorectal cancer.
— User:Kashmiri 17:09, 22 January 2023 (UTC)- As other editors have observed, PMID:25790229 is an poor/unreliable source, and simply not usable here. Bon courage (talk) 07:46, 18 January 2024 (UTC)
- You grossly misrepresented the findings, ignoring the primary endpoint.
- I have an idea of Hobs opinion, but instead I'm going to give you mine. For us encyclopedia editors, Ogata et al is entirely unimportant, because of WP:RS and WP:MEDRS. - Roxy the dog 16:21, 22 January 2023 (UTC)
- The Findings section contained
- "Overall survival"- not significant
- "RFS" - not significant
- "CSS rate" - barely significant at 3.7%
- "Cancer recurred" - no statement about significance.
- So, we have the Multiple comparisons problem - there are four outcomes, one of which is barely significant. Because of multiple comparisons, the significances need to be adapted, making the third one not significant either. But the most relevant finding is obviously the first one, overall survival. (Hint: If the treatment tends to kill the patient as well as the cancer, that is not helpful.) That is the one Kashmiri talked about, and there is nothing wrong with that. Can you please stop trying to cram cherry-picked results into the article? --Hob Gadling (talk) 08:01, 18 January 2024 (UTC)
- Diffs showing cherry-picked results being crammed into the article? I can't stop doing what I haven't started. Back off with the personal attack, eh? The problem is I'm getting a lot of pushback when I'm removing demonstrably false, defamatory information violating BLP that I stumbled upon. Does MEDRS say anything about the Multiple comparisons problem? Perhaps it should. But, does V? No. When it comes to BLP violations, wp:V is what matters. That makes it usable here, even though it's a single study. I notice no one is pushing back on this central point. But more importantly, true or false: Cancer Specific Survival was the SOLE, PRE-selected, primary endpoint, and it DOUBLED.
True. Kind of blows apart your whole argument. Kashmiri grossly misrepresented the sole, primary endpoint (p=0.037 for CSS) as not statistically significant when it was. Y'all are defending that. And then K called it basic research - huh? Clinical studies are basic research now? Regarding 3: From the article:
so why do you say 3.7%? "3.7" doesn't even appear in the paper! FR! BTW, the bulk of the shit-ton of negative info about neoplastons in the article is sourced only to non-MEDRS-compliant sources. If I was keen to make neoplastons look better, I could cut most of the negative info out of the article based on MEDRS. How 'bout we compromise, leave all that in, and take out the false info I'm objecting to? RudolfoMD (talk) 08:38, 18 January 2024 (UTC)Nevertheless, the CSS rate was significantly higher in the AN arm versus the control arm (n=33) with a median survival time 67 months (95%CI 43-not calculated) versus 39 months (95%CI 28-47) (p=0.037) and 5 year CSS rate 60% versus 32% respectively.
Diffs showing cherry-picked results being crammed into the article?
Aren't you trying to put what you call "Good Evidence for Antineoplaston Efficacy from Japan" into the article? It is one primary study out of many, so it is cherry-picking. Even if we regard only this study, you are cherry-picking the one significant result out of four.Back off with the personal attack, eh?
A "personal attack" is something that refers to the person instead of what the person is saying or doing. I referred to what you were saying or doing. That is not a personal attack.Does MEDRS say anything about the Multiple comparisons problem
MEDRS does not explicitly mention it, but considering it is part of good practice. If you avoid primary studies like this one, that is a good start avoiding the multiple comparisons problem.Cancer Specific Survival was the SOLE, PRE-selected, primary endpoint
Was the "PRE-selected, primary endpoint" published before the result was? I cannot find it.why do you say 3.7%?
3.7% = 0.037.the bulk of the shit-ton of negative info about neoplastons in the article is sourced only to non-MEDRS-compliant sources
WP:PARITY say,In an article on a fringe topic, if a notable fringe theory is primarily described by amateurs and self-published texts, verifiable and reliable criticism of the fringe theory need not be published in a peer-reviewed journal.
--Hob Gadling (talk) 10:18, 18 January 2024 (UTC)- You can't even find a diff showing I called anything "Good Evidence for Antineoplaston Efficacy from Japan," Hob. Or that I tried to put the article you are trying to refer to into the article. So...Your
Can you please stop trying to cram cherry-picked results into the article?
when I had done nothing of the sort = false and disparaging but OK, a "not personal" attack, so you're sort of right. RudolfoMD (talk) 13:32, 18 January 2024 (UTC)- "Good Evidence for Antineoplaston Efficacy from Japan" is the title of this thread. You are writing contributions to it, and I got the impression that you are supporting the IP that started the thread and trying to get that study cited by the article.
- So you are not trying to get the Ogata study into the article? Then what are you trying to achieve here by talking about the study? This page is for discussing improvements to the article. It is not a forum. --Hob Gadling (talk) 15:49, 18 January 2024 (UTC)
You can't even find a diff showing Or that I tried to put the article you are trying to refer to into the article. So...
- diff. MrOllie (talk) 18:27, 18 January 2024 (UTC)
- You can't even find a diff showing I called anything "Good Evidence for Antineoplaston Efficacy from Japan," Hob. Or that I tried to put the article you are trying to refer to into the article. So...Your
- Diffs showing cherry-picked results being crammed into the article? I can't stop doing what I haven't started. Back off with the personal attack, eh? The problem is I'm getting a lot of pushback when I'm removing demonstrably false, defamatory information violating BLP that I stumbled upon. Does MEDRS say anything about the Multiple comparisons problem? Perhaps it should. But, does V? No. When it comes to BLP violations, wp:V is what matters. That makes it usable here, even though it's a single study. I notice no one is pushing back on this central point. But more importantly, true or false: Cancer Specific Survival was the SOLE, PRE-selected, primary endpoint, and it DOUBLED.
- The Findings section contained
BLP violation
Other investigators have been successful in duplicating some of his results. It's my understanding that BLP requires removing the false claim that "other investigators have not been successful in duplicating" any of his results. We all know: Contentious material about living persons that is unsourced or poorly sourced must be removed immediately from the article and its talk page, especially if potentially libellous. This is obviously poorly sourced as it is contradicted by w:V .gov sources. I've pulled it. If anyone want's to revert, I urge a visit to Misplaced Pages:Biographies_of_living_persons/Noticeboard as a next, pre-revert step. RudolfoMD (talk) 04:21, 18 January 2024 (UTC)
- Classic WP:CRYBLP. Questions of experimental replication are not biographical; you just need a reliable source saying whether the replication has happened (or not). Bon courage (talk) 07:48, 18 January 2024 (UTC)
Oddly, I can't find an NIH publication.
A footnote in a journal article on the Phase III trial that the wipedia article uses as a source:
is
§ See M. R. Hammer, Burzynski antineoplaston case study: conflict issues and recommendations. Office of Alternative Medicine report, National Institutes of Health, 1996; M. Hammer, The management of dispute and judgment process in controversial complementary and alternative medicine research. Office of Alternative Medicine Report, National Institutes of Health, 1996.
Has anyone found a copy of it anywhere online? I can't with google.
The article is by Hammer and he is citing his own work ... which I can't find. Curious. Also, he doesn't put it in the References section endnote like all his other sources, but rather in a footnote. Also curious. The resulting procedures - methods of social management of research in controversial areas to allow them to proceed anyway that the reference documents haven't been employed in a subsequent second attempt. Curious as well. RudolfoMD (talk) 04:24, 17 January 2024 (UTC)
References
- Hammer, Mitchell R.; Jonas, Wayne B. (March 2004). "Managing Social Conflict in Complementary and Alternative Medicine Research: The Case of Antineoplastons". Integrative Cancer Therapies. 3 (1): 59–65. doi:10.1177/1534735404263448. PMID 15035877.
- WWayne Jonas should not be cited, he's a quackery apologist (e.g. author of a number of papers promoting the entirely refuted nonsense that is homeopathy). Guy (help! - typo?) 19:39, 17 January 2024 (UTC)
- Huh? I am not looking for or seeking to cite "WWayne Jonas" <sic> work in the encyclopedia. And given your recent dubious evaluation of what is "excellent", I'm less interested in what you are sharing, un-prompted and citation-free. I'm looking for M. R. Hammer's 1996 NIH publication, not Hammer and Jonas' 2004 ICT publication, which is obviously readily available at the linked source I provided - <ref name=HammerICT>. Do you have anything helpful to offer about what I'm actually expressing curiosity? RudolfoMD (talk) 02:36, 18 January 2024 (UTC)
- You kind've are. Wayne Jonas was director of the Office of Alternative Medicine at the time. The OAM (now the NCCIH) is independent from the rest of the NIH, so you probably won't find their reports in the same places as the rest of the NIH's output. It wouldn't be usable on Misplaced Pages anyway. MrOllie (talk) 02:52, 18 January 2024 (UTC)
- Thanks for the info. Why wouldn't it be usable with subject matter where MEDRS doesn't apply? RudolfoMD (talk) 04:07, 18 January 2024 (UTC)
- RudolfoMD, you wrote: "I am not looking for or citing "WWayne Jonas" <sic> work." Actually you are. Jonas is one of the authors of "Managing Social Conflict in Complementary and Alternative Medicine Research: The Case of Antineoplastons". Mitchell R. Hammer, PhD, and Wayne B. Jonas, MD
- So Jonas is one of the authors, and, as noted above by Guy, he also happens to be a promotor of quack medicine. -- Valjean (talk) (PING me) 05:46, 18 January 2024 (UTC)
- I would be amazed if you got consensus that a report from the OAM is RS even in non medical contexts, let alone for Burzynski-related stuff. The OAM was set up in the first place because Sen. Tom Harkin was a believer (specifically in antineoplastons and bee pollen therapy) and he set the office up and kept it funded to promote those treatments. The whole thing is a political exercise that has very little to do with science. MrOllie (talk) 18:33, 18 January 2024 (UTC)
- Thanks for the info. Why wouldn't it be usable with subject matter where MEDRS doesn't apply? RudolfoMD (talk) 04:07, 18 January 2024 (UTC)
- You kind've are. Wayne Jonas was director of the Office of Alternative Medicine at the time. The OAM (now the NCCIH) is independent from the rest of the NIH, so you probably won't find their reports in the same places as the rest of the NIH's output. It wouldn't be usable on Misplaced Pages anyway. MrOllie (talk) 02:52, 18 January 2024 (UTC)
- Huh? I am not looking for or seeking to cite "WWayne Jonas" <sic> work in the encyclopedia. And given your recent dubious evaluation of what is "excellent", I'm less interested in what you are sharing, un-prompted and citation-free. I'm looking for M. R. Hammer's 1996 NIH publication, not Hammer and Jonas' 2004 ICT publication, which is obviously readily available at the linked source I provided - <ref name=HammerICT>. Do you have anything helpful to offer about what I'm actually expressing curiosity? RudolfoMD (talk) 02:36, 18 January 2024 (UTC)
“ | If I say 1996+2=2004, then 1996+2=2004. | ” |
- O'Brien RudolfoMD (talk) 07:20, 18 January 2024 (UTC)
Questionable WP:ABOUTSELF source
The source https://pubmed.ncbi.nlm.nih.gov/3527634/ should really not be used for anything like a factual claim, as it's ABOUTSELF material - Burzynski's own self-serving statement, with no objective review, and including contentious and likely tendentious claims like "The treatment was free from significant side-effects and resulted in objective response in a number of advanced cancer cases". After half a century, there should be an independent source for this, and almost certainly would be, if it were objectively true. Guy (help! - typo?) 19:38, 17 January 2024 (UTC)
Claim of copyright violation
The wording is a bit close, but it is a paraphrase. Rather than deleting it, suggest a reword. MrOllie (talk) 02:59, 18 January 2024 (UTC)
- False. It's not a paraphrase. It's bloody verbatim copying by JzG contrary to a Misplaced Pages policy with legal considerations. WP:C / COPYRIGHT. RudolfoMD (talk) 04:13, 18 January 2024 (UTC)
- It's called plagiarism. Putting it in quotes and attributing it solved the problem. -- Valjean (talk) (PING me) 07:17, 18 January 2024 (UTC)
- Now it's more messed up. a cancer expert and an FDA official told Reuters and Reuters said aren't the same. RudolfoMD (talk) 04:40, 18 January 2024 (UTC)
- Well, perhaps you should have left well alone, then, since your clumsy attempt to fix the “problem” of reality rejecting Burzynski’s piss therapy seems to be the root cause of all this drama. Guy (help! - typo?) 09:06, 22 January 2024 (UTC)
Talk page vandalism.
Beware Talk page vandalism removing active discussion. RudolfoMD (talk) 06:49, 18 January 2024 (UTC)
- Now a third time. I was archiving old and inactive content and didn't notice you had left comments in some of them. Now you have restored the whole thing. I'll be more careful with the next try. -- Valjean (talk) (PING me) 07:07, 18 January 2024 (UTC)
- To avoid this in the future, don't comment on such old threads. Start a new thread. -- Valjean (talk) (PING me) 07:14, 18 January 2024 (UTC)
- Thank you! Such helpful advice. SO kind of you. RudolfoMD (talk) 07:21, 18 January 2024 (UTC)
Notice
{{BLP noticeboard}} RudolfoMD (talk) 09:05, 18 January 2024 (UTC)
Semi-protected edit request on 5 March 2024
This edit request has been answered. Set the |answered= or |ans= parameter to no to reactivate your request. |
The article is slanderous. Reliable source : Burzynski documentary. Cancer cure cover up. It’s big business. He’s not a quack. Big $ has all the power to run smeer campaigns on anyone they like. The fda & Texas medical board were so despicable & unashamedly bold in taking him down because of his non invasive EFFECTIVE treatment of cancer. There are so many testimonials court appearances protests & news reports in this 2 part documentary it’s mind blowing. Deedssky (talk) 05:57, 5 March 2024 (UTC)<Eric Merola>
- Not done That documentary is not a reliable source. Far from it. Bon courage (talk) 06:01, 5 March 2024 (UTC)
Semi-protected edit request on 11 October 2024
This edit request has been answered. Set the |answered= or |ans= parameter to no to reactivate your request. |
Under "Antineoplaston Therapy":
Since 2011, the clinic has marketed itself as offering "personalized gene-targeted cancer therapy", which has stirred further controversy. David Gorski argues that the concept of "personalised cancer therapy" is "more of a marketing term than a scientifically meaningful description". According to Gorski, a research oncologist, it appears unlikely that the Burzynski clinic would indeed be able to actually personalise gene-targeting therapies, i.e., "identify who would benefit from specific targeted therapies simply from blood tests," as Burzynski claims, since there are no proven methods to achieve this. Consequently, many reject Burzynski's claim of offering personalized medicine, because in reality his patients are administered untested combinations of various approved and unapproved medications, without a sound rationale for a given combination and without "any concern for potential adverse reactions".
I suggest removing this paragraph or reworking it entirely. Testing for genetic mutations is the premise of finding the appropriate therapy for many types of cancer. While Dr. Gorski may have a point regarding the semantics, and while his point is somewhat related to the Burzynski Clinic's claims of providing "personalized" services, a reader might draw the conclusion that genetic testing for cancer treatment does not exist. Ajordan538 (talk) 19:05, 11 October 2024 (UTC)
Not done for now: please establish a consensus for this alteration before using the {{Edit semi-protected}}
template. PianoDan (talk) 20:22, 18 October 2024 (UTC)
Help I just want to add another film name
I tried to edit this page to add in another film that was directed by Eric Merola with a release date of 2016. The name of the film is (Burzynski: Cancer Cure Cover Up). For some reason I ended up being posted in the M.R. Hammer talk. I know the subject matter is controversial, however the film I mentioned is clearly mentioned on the IMDb website and I just watched it on the Tubi streaming service. This film clearly exists. Thanks for any help in this matter Mrgrimfate (talk) 02:15, 31 December 2024 (UTC)
Categories:- Misplaced Pages controversial topics
- Biography articles of living people
- B-Class Skepticism articles
- Mid-importance Skepticism articles
- WikiProject Skepticism articles
- B-Class medicine articles
- Low-importance medicine articles
- Misplaced Pages requested images of medical subjects
- All WikiProject Medicine pages
- B-Class Alternative medicine articles
- B-Class United States articles
- Low-importance United States articles
- B-Class United States articles of Low-importance
- B-Class Texas articles
- Low-importance Texas articles
- WikiProject Texas articles
- Misplaced Pages requested photographs in Texas
- WikiProject United States articles
- Misplaced Pages pages referenced by the press
- Pseudoscience articles under contentious topics procedure